
==== Front
ACS OmegaACS OmegaaoacsodfACS Omega2470-1343American Chemical Society 3145787510.1021/acsomega.7b01493ArticleDiastereoselective Synthesis of Morphan Derivatives
by Michael and Hetero-Michael Addition of 1,1-Enediamines to Quinone
Monoketals Hu Xing-Mei Luo Da-Yun Zi Quan-Xing Lin Jun *Yan Sheng-Jiao *Key Laboratory of Medicinal Chemistry
for Natural Resource (Yunnan University), Ministry of Education, School
of Chemical Science and Technology, Yunnan
University, Kunming 650091, P. R. China* E-mail: linjun@ynu.edu.cn. Phone/Fax: +86 87165031633 (J.L.).* E-mail: yansj@ynu.edu.cn. Phone/Fax: +86 87165031633 (S.-J.Y.).02 01 2018 31 01 2018 3 1 8 21 09 10 2017 19 12 2017 Copyright © 2018 American Chemical Society2018American Chemical SocietyThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

A general and concise
method was developed for the synthesis of
highly functionalized morphans 3–4 by the Michael
and hetero-Michael addition reaction of different types of quinone
monoketals 1 and 1,1-enediamines 2 in ethanol
or 1,4-dioxane at reflux. This method is suitable for the efficient
parallel syntheses of N-containing heterocycles. A library of highly
functional morphan derivatives was easily constructed using the Michael/hetero-Michael
reaction.

document-id-old-9ao7b01493document-id-new-14ao-2017-01493jccc-price
==== Body
Introduction
Morphan (2-azabicyclo[3.3.1]nonane)
derivatives are becoming more
and more important in medicine1,2 and are a common structural
motif in many biologically active natural products and pharmacologically
active molecules, such as the immunosuppressant FR9014834,3 daphniphyllum alkaloids (cytotoxic agents),4 opioid agonists (e.g., compound A),5 opioid receptor antagonists (e.g.,
morphine,6 compound B,7 naloxone,8 naltrexone,9 TENA,10 GNTI,11 ANTI,12 BNTI,13 and C-CAM14), and
madangamines15 (Figure 1).16 Morphan derivatives
have been studied based on their broad spectrum of biological activities.
Although many methods have been developed for the synthesis of morphan
derivatives by organic or pharmaceutical chemists for many years,17−21 these approaches usually require metal catalysts under strict anhydrous
conditions or multistep syntheses. Consequently, it is desirable and
important to develop concise, highly regioselective, and environmentally
friendly methods for building up a highly substituted morphan derivative
library.

Figure 1 Biologically active morphans and targeted compounds.

Quinone monoketals can be easily obtained from
phenols in a single
step22 and are widely used for the synthesis
of various structurally complex molecules.23,24 Though quinone monoketals contain two unsaturated C=C bonds,
they usually undergo 1,4-nucleophilic addition.25,26 Their reaction via double Michael addition is very seldom.27

Cyclic 1,1-enediamines (EDAMs) are a fascinating
and versatile
building block28 that is widely used to
synthesize various fused heterocyclic compounds including quinolones,29 isoquinolin-1-imines,30 indoles,31 indolin-2-ones,32 isocoumarins,33 pyridines,34 and pyrroles.35 Many
of these compounds have a wide range of biological activities, such
as antitumor,36 herbicide, pesticide,37 antianxiety,38 antileishmanial,39 and antibacterial.40 However, acyclic EDAMs have not been considered for many years.
Seldom literature reports have shown that EDAMs serve as bisnucleophiles
(α-carbon and N as nucleophilic sites) and react with biselectrophiles
to produce fused heterocyclic compounds.41 To date, to the best of our knowledge, incorporation of the two
nucleophilic sites (α-C and N) through the Michael and hetero-Michael
addition of EDAMs to form bridged-ring frame compounds has not been
reported.

Our group recently obtained the bridged-ring frame
morphans with
an immunosuppressive activity based on cyclic EDAM building blocks.42a To get molecularly diverse morphans and further
investigate more active immunosuppressants,42b we designed and synthesized novel target compounds morphans by the
Michael/hetero-Michael addition reaction of EDAMs through the two
reaction sites (α-C and N).

Results and Discussion
Here, we report a novel synthesis method to produce morphan derivatives 3 and 4 by refluxing the mixture of quinone monoketals 1 and EDAMs 2 in ethanol or 1,4-dioxane, promoted
by cesium carbonate (Scheme 1). The target compounds were obtained in good yields (58–90%).

Scheme 1 Strategy for the Michael/Hetero-Michael Addition Synthesis of Morphans 3 and 4
First, we evaluated the Michael/hetero-Michael addition
reaction
of quinone monoketals 1 and EDAMs 2. The
mixture (1a/2a = 1.1:1) was treated under
various conditions (Table 1, entries 1–20). The results demonstrated that the
reaction could not proceed at reflux in 1,4-dioxane under without-additive
conditions (Table 1, entry 1). Et3N and K2CO3 were
selected as promoters to test the reaction under different solvents
(ethanol, acetonitrile, 1,4-dioxane, and toluene) and reflux conditions.
The result is still negative (Table 1, entries 2–9). Then, Cs2CO3 (2.0 equiv) was charged into the different solvents and refluxed
for 6 h (Table 1, entries
10–14). As a result, with ethanol as the solvent, the reaction
can proceed smoothly to give the target product 3a in
a 90% yield. A stronger alkali, t-BuOK, was used
in aprotic solvents (acetonitrile and 1,4-dioxane) and protic solvents
(t-BuOH). The results showed that the reaction becomes
more complex and cannot achieve a positive result as the alkaline
is too strong (Table 1, entries 15–17). Other organic alkalis including N,N-diisopropylethylamine (DIPEA), 1,8-diazabicyclo[5.4.0]-7-undecene
(DBU), and 1,4-diazabicyclo[2.2.2]octane (DABCO) could not promote
the reaction smoothly even under the optimal solvent ethanol (Table 1, entries 18–20).
The results demonstrate that the optimal reaction conditions for the
synthesis of morphan derivatives were ethanol or 1,4-dioxane as the
solvent and Cs2CO3 as the promoter under reflux
for 6 h in a 89–90% yield (Table 1, entries 10 vs 13).

Table 1 Optimized
Conditions for the Synthesis
of 3aa
entry	solvent	base	T (°C)	time (h)	yieldb (%)	
1	1,4-dioxane	−	reflux	12	n.r.	
2	EtOH	Et3N	reflux	12	n.r.	
3	acetonitrile	Et3N	reflux	12	n.r.	
4	1,4-dioxane	Et3N	reflux	12	n.r.	
5	toluene	Et3N	reflux	12	n.r.	
6	acetone	K2CO3	reflux	12	n.r.	
7	EtOH	K2CO3	reflux	12	n.r.	
8	THF	K2CO3	reflux	12	n.r.	
9	1,4-dioxane	K2CO3	reflux	12	n.r.	
10	EtOH	Cs2CO3	reflux	6	90	
11	acetonitrile	Cs2CO3	reflux	6	78	
12	THF	Cs2CO3	reflux	6	n.r.	
13	1,4-dioxane	Cs2CO3	reflux	6	89	
14	toluene	Cs2CO3	reflux	6	n.r.	
15	acetonitrile	t-BuOK	reflux	6	complex	
16	1,4-dioxane	t-BuOK	reflux	6	complex	
17	t-BuOH	t-BuOK	reflux	6	complex	
18	EtOH	DIPEA	reflux	12	n.r.	
19	EtOH	DBU	reflux	12	n.r.	
20	EtOH	DABCO	reflux	12	n.r.	
a Reaction conditions: 1a (1.1 mmol), 2a (1.0 mmol), promoter (2.0 mmol),
and
solvent (15 mL).

b Isolated
yield based on EDAM 2a (n.r. = no reaction).

Encouraged by this result, we explored
the scope and limitations
of the double Michael reactions involving different quinone monoketals 1 with various EDAMs 2 (Table 2, 3a–3c′) in ethanol.
The results showed that the electron-withdrawing group (F and Cl)-substituted N-benzyl EDAM can achieve higher yield than the electron-donating
group (Me and MeO) EDAM (Table 2, 3a vs 3c; 3f vs 3h). The N-phenyl-ethyl EDAM follows the
same rule. Longer chain EDAMs usually produce the target compounds
in lower yields (Table 2, 3b vs 3d; 3k vs 3l; and 3n vs 3p). In addition, sterically
hindered quinone monoketals can greatly decrease the yields (Table 2, 3s–3x).

Table 2 Michael/Hetero-Michael Addition for
the Synthesis of Morphan Derivatives 3a,b
a Reagents and conditions: 1 (1.1 mmol), 2 (1.0 mmol), Cs2CO3 (2.0 mmol), and EtOH (15.0 mL).

b Isolated yield based on 2.

It must be noted that the Michael/hetero-Michael
addition reaction
has very high regioselectivity and diastereoselectivity. As a result,
only the target product 3 was obtained in the form of
compounds 3a–3c′ (no diastereoisomers of 3a–3c′ were detected) (Table 2).

To further explore the sterically
hindered EDAMs, N,N-bis-substituted
EDAMs 2 have been used as substrates to react with quinone
monoketals 1a in EtOH (Table 3, entries 1–2). As a result, we can
get only moderate yields (76–80%). As 1,4-dioxane replaces
EtOH as the solvent under the same conditions (Table 3, entries 3–4), we find that the reaction
can get higher yields (80–88%). We believe that the sterically
hindered EDAMs make the reaction difficult at lower temperature (at
reflux in EtOH) compared with at higher temperature (at reflux in
1,4-dioxane). Consequently, different sterically hindered N,N-bis-substituted
EDAMs 2 are used as substrates to react with various
quinone monoketals in 1,4-dioxane for the synthesis of 4a–4o (Table 3, entries
3–17). Generally, EDAMs with electron-withdrawing groups (F
and Cl) often can obtain higher yields than electron-donating group
EDAMs (Table 3, entries
3 vs 4; 10 vs 13–14). Longer chain EDAMs get the target compounds
in lower yields (Table 3, entries 13 vs 15). The mixture of sterically hindered quinone monoketals
(1e and 1f) and EDAMs 2 was
refluxed in ethanol under the same conditions (Table 3, entries 18–19). The results demonstrated
that the steric hindrance effects on quinone monoketals 1 cannot make the reaction proceed smoothly.

Table 3 Michael/Hetero-Michael
Addition for
the Synthesis of Morphan Derivatives 4a,b
entry	1	n	R	R1	R2	R3	R′	4	yieldb [%]	
1	1a	1	Me	OMe	H	H	4-FC6H4	4a	80c	
2	1a	1	Me	OMe	H	H	4-MeOC6H4	4b	76c	
3	1a	1	Me	OMe	H	H	4-FC6H4	4a	88d	
4	1a	1	Me	OMe	H	H	4-MeOC6H4	4b	80d	
5	1a	1	Me	OMe	H	H	2,4-FC6H3	4c	89d	
6	1a	1	Me	OMe	H	H	3,4-FC6H3	4d	88d	
7	1a	2	Me	OMe	H	H	4-FC6H4	4e	88d	
8	1a	2	Me	OMe	H	H	3-FC6H4	4f	84d	
9	1a	2	Me	OMe	H	H	2-FC6H4	4g	86d	
10	1a	2	Me	OMe	H	H	4-ClC6H4	4h	83d	
11	1a	2	Me	OMe	H	H	3-ClC6H4	4i	83d	
12	1a	2	Me	OMe	H	H	2-ClC6H4	4j	81d	
13	1a	2	Me	OMe	H	H	C6H5	4k	78d	
14	1a	2	Me	OMe	H	H	4-MeC6H4	4l	75d	
15	1a	3	Me	OMe	H	H	C6H5	4m	71d	
16	1b	1	Et	OEt	H	H	C6H5	4n	65d	
17	1c	1	CH2CH2O	H	H	H	4o	78d	
18	1e	1	Me	OMe	Me	H	C6H5	4p	n.r.d	
19	1f	2	Me	OMe	H	Me	C6H5	4q	n.r.d	
a Reaction conditions: 1 (1.1 mmol), 2 (1.0
mmol), and Cs2CO3 (2.0 mmol).

b Isolated yield based on 2.

c EtOH (15.0 mL).

d 1,4-Dioxane (15.0 mL).

To achieve the molecular diversity
of the products, N,O-acetal (5a) and N,S-acetal (5b),43 which have different structures,
were applied as substrates
to react with quinone monoketals 1a–1b to synthesize
the products 6a–6c in good to excellent yields
(71–85%) (Table 4).

Table 4 Michael/Hetero-Michael Addition for
the Synthesis of Morphan Derivatives 6a,b
a Reagents and conditions: 1 (1.1 mmol), 5 (1.0 mmol), Cs2CO3 (2.0 mmol), and 1,4-dioxane (15.0 mL).

b Isolated yield based on 5.

To confirm the structure of the
morphan derivatives, 3b, 3e, 3u, and 4a were selected
as the representative compounds and were characterized by X-ray crystallography,
as shown in Figure 2 (CCDC 1546771 and CCDC 1546772) and Figure 3 (CCDC 1578670 and CCDC 1546773) (see the Supporting Information).

Figure 2 ORTEP diagrams of 3b (left) and 3e (right);
ellipsoids are drawn at the 30% probability level.

Figure 3 ORTEP diagrams of 3u (left) and 4a (right);
ellipsoids are drawn at the 30% probability level.

A proposed mechanism of the base-promoted Michael/hetero-Michael
addition reaction is shown in Scheme 2. Initially, the quinone monoketals 1 react
with EDAMs 2 via Michael addition to form the intermediate 7. Then, intermediate compound 8 is obtained
from intermediate 7 by imine–enamine tautomerization.
Finally, intermediate 8 is followed by intramolecular
hetero-Michael addition to produce compounds 3–4.

Scheme 2 Mechanism Hypotheses for the Synthesis of Target Compounds 3–4
Conclusions
We developed a procedure for the simple
synthesis of a variety
of potentially biologically active morphan derivatives based on the
Michael/hetero-Michael addition reaction. Accordingly, a molecularly
diverse morphan library was rapidly constructed in one-pot in good
yields by simply refluxing a reaction mixture of quinone monoketals
and EDAMs in an environmentally friendly solvent (ethanol) or 1,4-dioxane,
promoted by Cs2CO3.

Experimental Section
General
Methods
All compounds were fully characterized
by spectroscopic data. NMR spectra were recorded on a Bruker DRX300,
DRX400, or DRX500, chemical shifts (δ) are expressed in ppm, J values are given in Hz, and deuterated DMSO-d6 or CDCl3 was used as the solvent. IR spectra
were recorded on a FT-IR Thermo Nicolet Avatar 360 using a KBr pellet.
The reactions were monitored by thin-layer chromatography (TLC) using
silica gel GF254. The melting points were determined on
an XT-4A melting point apparatus and are uncorrected. High-resolution
mass spectrometry (HRMS) was performed on an Agilent LC/Msd TOF instrument.
X-ray diffraction was obtained by APEX DUO.

All chemicals and
solvents were used as received without further purification unless
otherwise stated. All chemicals were purchased from Adamas-beta. Column
chromatography was performed on silica gel (Qingdao, 200–300
mesh).

Compounds 1 were prepared according to the
literature.44,45 Compounds 2 were
prepared according to the literature.46

General Procedure for the Synthesis of Compounds 3
Quinone monoketals 1 (1.1 mmol), EDAMs 2 (1.0 mmol), Cs2CO3 (2.0 mmol), and
ethanol (15 mL) were charged into a 25 mL round-bottom flask. The
mixture was kept at reflux for about 6 h and monitored by TLC until
the quinone monoketal 1 substrate was completely consumed.
After the reaction was completed, the reaction system was cooled to
room temperature. The reaction mixture was poured into 25 mL of water
and 50 mL of ethyl acetate for extraction and separation. Then, the
crude product was concentrated by distillation under reduced pressure,
purified by column chromatography (petroleum ether/ethyl acetate =
1:2), and produced a series of compounds 3 in a 58–90%
yield.

(1R,5R)-3-((4-Fluorobenzyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(3a)
Yellow solid; mp 130.3 °C; IR (KBr):
3424, 1720, 1619, 1563, 1381, 1223, 1057, 755 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 2.19–2.22 (m, 1H, COCH2), 2.35–2.38
(m, 1H, COCH2CHN), 2.67–2.71 (m, 1H, COCH2), 2.81–2.85 (m, 1H, COCH2CHN), 3.12 (s, 3H, OCH3), 3.34 (s, 3H, OCH3), 3.70–3.74 (m, 1H,
CH), 3.90–3.94 (m, 1H, CHN), 4.48–4.51 (m, 2H, CH2N), 7.20–7.32 (m, 4H, ArH), 8.08 (br, 1H, NH), 10.97
(br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 37.4, 41.4, 43.8, 46.2, 48.6, 48.9, 50.6,
96.4, 107.3, 115.9 (d, J = 21.3 Hz), 129.5 (d, J = 7.5 Hz), 133.3, 153.7, 162.0 (d, J =
241.3 Hz), 208.3; 19F NMR (467 MHz, DMSO-d6): δ = −115.2; HRMS (EI+): m/z calcd for C17H21FN3O5 [M + H]+, 366.1460; found,
366.1460.

(1R,5R)-3-(Benzylamino)-9,9-dimethoxy-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(3b)
Yellow solid; mp 256.5–257.5 °C;
IR (KBr): 3423, 3254, 1720, 1621, 1562, 1386, 1267, 1053, 741 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 2.22–2.25 (m, 1H, COCH2), 2.39–2.41 (m, 1H, COCH2CHN), 2.50–2.51
(m, 1H, COCH2), 2.69–2.70 (m, 1H, COCH2CHN), 3.14 (s, 3H, OCH3), 3.35 (s, 3H, OCH3), 3.74–3.76 (m, 1H, CH), 3.92–3.96 (m, 1H, CHN), 4.52–4.57
(m, 2H, CH2N), 7.26–7.41 (m, 5H, ArH), 8.13 (br,
1H, NH2), 11.01 (br, 1H, NH2); 13C NMR (125 MHz, DMSO-d6): δ = 37.4,
41.4, 44.5, 46.2, 48.7, 48.9, 50.7, 96.5, 107.3, 127.4, 127.9, 129.1,
137.0, 153.7, 208.3; HRMS (EI+): m/z calcd for C17H22N3O5 [M + H]+, 348.1554; found, 348.1556.

(1R,5R)-9,9-Dimethoxy-4-nitro-3-(phenethylamino)-2-azabicyclo[3.3.1]non-3-en-7-one
(3c)
Yellow solid; mp 182.6 °C; IR (KBr):
3440, 1720, 1621, 1561, 1384, 1252, 1027, 754 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 2.24–2.27 (m, 1H, COCH2), 2.36–2.39
(m, 1H, COCH2CHN), 2.68–2.72 (m, 1H, COCH2), 2.83–2.87 (m, 1H, COCH2CHN), 3.15 (s, 3H, OCH3), 3.74 (s, 3H, OCH3), 3.73–3.74 (m, 1H,
CH), 3.98–4.02 (m, 1H, CHN), 6.94–6.96 (m, 2H, ArH),
7.22–7.24 (m, 2H, ArH), 8.09 (br, 1H, NH), 10.92 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ
= 37.4, 41.4, 44.2, 46.2, 48.7, 48.9, 50.7, 55.6, 96.5, 107.3, 114.6,
128.8, 129.0, 153.5, 159.2, 208.3; HRMS (EI+): m/z calcd for C18H24N3O6 [M + H]+, 378.1660; found,
378.1659.

(1R,5R)-9,9-Dimethoxy-4-nitro-3-(phenethylamino)-2-azabicyclo[3.3.1]non-3-en-7-one
(3d)
White solid; mp 186.4 °C; IR (KBr):
3430, 1721, 1621, 1564, 1345, 1287, 1034, 754 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 2.27–2.36 (m, 2H, COCH2, COCH2CHN), 2.66–2.67 (m, 1H, COCH2), 2.82–2.87
(m, 3H, COCH2CHN, CH2Ar), 3.16 (s, 3H, OCH3), 3.34 (s, 3H, OCH3), 3.44–3.46 (m, 2H,
CH2N), 3.70–3.71 (m, 1H, CH), 3.92–3.96 (m,
1H, CHN), 7.23–7.33 (m, 5H, ArH), 8.03 (br, 1H, NH), 10.69
(br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 34.8, 37.7, 41.9, 43.2, 46.7, 49.1, 49.3,
51.1, 96.9, 107.5, 127.4, 129.3, 129.7, 139.2, 153.9, 208.7; HRMS
(EI+): m/z calcd for
C18H24N3O5 [M + H]+, 326.1710; found, 326.1713.

(1R,5R)-3-((3-Chlorophenethyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(3e)
White solid; mp 202.8–203.3 °C;
IR (KBr): 3423, 1721, 1621, 1570, 1344, 1288, 754 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 2.28–2.37 (m, 2H, COCH2, COCH2CHN), 2.67–2.71 (m, 1H, COCH2), 2.83–2.89
(m, 3H, COCH2 CHN, CH2Ar), 3.17 (s, 3H, OCH3), 3.34 (s, 3H, OCH3), 3.44–3.49 (m, 2H,
CH2N), 3.69–3.73 (m, 1H, CH), 3.94–3.98 (m,
1H, CHN), 7.22–7.24 (m, 1H, ArH), 7.29–7.36 (m, 2H,
ArH), 7.37–7.41 (m, 1H, ArH), 8.06 (br, 1H, NH), 10.70 (br,
1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 33.9, 37.3, 41.4, 42.3, 46.2, 48.7, 48.9, 50.6,
96.4, 107.1, 127.0, 128.1, 129.2, 130.7, 133.5, 141.3, 153.5, 208.4;
HRMS (EI+): m/z calcd
for C18H23ClN3O5 [M +
H]+, 396.1321; found, 396.1323.

(1R,5R)-9,9-Diethoxy-3-((4-fluorobenzyl)amino)-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(3f)
Yellow liquid; mp 130.0 °C; IR (KBr):
3416, 3258, 1719, 1619, 1563, 1344, 1057, 755 cm–1; 1H NMR (500 MHz, CDCl3): δ = 1.02–1.04
(m, 3H, CH3CH2O), 1.18–1.20 (m, 3H, CH3CH2O), 2.40–2.44 (m, 1H, COCH2), 2.56–2.57 (m, 2H, COCH2, COCH2CHN),
2.71–2.75 (m, 1H, COCH2CHN), 3.33–3.43 (m,
2H, CH2O), 3.52–3.59 (m, 2H, CH2O), 3.72–3.76
(m, 1H, CH), 4.04–4.08 (m, 1H, CHN), 4.33–4.44 (m, 2H,
CH2N), 6.89–6.92 (m, 2H, ArH), 7.06–7.09
(m, 2H, ArH), 8.32 (br, 1H, NH); 13C NMR (125 MHz, CDCl3): δ = 10.3, 10.4, 33.5, 36.3, 39.8, 41.0, 46.8, 51.9,
51.9, 91.2, 104.3, 111.0 (d, J = 21.3 Hz), 124.1
(d, J = 21.3 Hz), 126.5, 149.0, 158.6 (d, J = 245.0 Hz), 203.8; HRMS (EI+): m/z calcd for C19H25FN3O5 [M + H]+, 394.1773; found, 394.1773.

(1R,5R)-3-(Benzylamino)-9,9-diethoxy-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(3g)
White solid; mp 172.0 °C; IR (KBr):
3417, 3250, 1720, 1616, 1567, 1348, 1092, 757 cm–1; 1H NMR (500 MHz, CDCl3): δ = 1.06–1.09
(m, 3H, CH3CH2O), 1.20–1.23 (m, 3H, CH3CH2O), 2.20–2.23 (m, 1H, COCH2), 2.36–2.39 (m, H, COCH2CHN), 2.68–2.72
(m, 1H, COCH2), 2.82–2.86 (m, 1H, COCH2CHN), 3.33–3.37 (m, 2H, CH3CH2), 3.61–3.71
(m, 2H, CH3CH2), 3.71–3.73 (m, 1H, CH),
3.91 (s, 1H, CHN), 4.52–4.55 (m, 2H, CH2N), 7.23–7.25
(m, 2H, ArH), 7.28–7.31 (m, 1H, ArH), 7.35–7.38 (m,
2H, ArH), 8.06 (br, 1H, NH), 11.035 (br, 1H, NH); 13C NMR
(125 MHz, CDCl3): δ = 15.5, 15.5, 38.2, 41.5, 44.3,
46.3, 51.4, 56.5, 56.7, 96.2, 107.5, 127.2, 127.9, 129.0, 137.2, 153.8,
208.4; HRMS (EI+): m/z calcd for C19H26N3O5 [M + H]+, 376.1867; found, 376.1872.

(1R,5R)-9,9-Diethoxy-3-((4-methoxybenzyl)amino)-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(3h)
Yellow solid; mp 116.3 °C; IR (KBr):
3416, 3251, 1719, 1614, 1561, 1345, 1056, 755 cm–1; 1H NMR (500 MHz, CDCl3): δ = 1.05–1.08
(m, 3H, CH3CH2O), 1.20–1.23 (m, 3H, CH3CH2O), 2.22–2.35 (m, 1H, COCH2), 2.36–2.39 (m, 1H, COCH2CHN), 2.68–2.72
(m, 1H, COCH2), 2.83–2.87 (m, 1H, COCH2CHN), 3.33–3.38 (m, 1H, CH3CH2O), 3.45–3.48
(m, 1H, CH3CH2O), 3.63–3.70 (m, 2H, CH3CH2O), 3.70–3.71 (m, H, CH), 3.74 (s, 3H,
CH3O), 3.90–3.94 (m, 1H, CHN), 4.42–4.45
(m, 2H, CH2N), 6.91–6.94 (m, 2H, ArH), 7.19–7.21
(m, 2H, ArH), 8.06 (br, 1H, NH), 10.96 (br, 1H, NH); 13C NMR (125 MHz, CDCl3): δ = 15.5, 15.5, 38.2, 41.5,
44.0, 46.3, 51.4, 55.6, 55.6, 56.5, 56.7, 96.2, 107.5, 114.5, 128.8,
153.6, 159.2, 208.4; HRMS (EI+): m/z calcd for C20H27N3NaO6 [M + Na]+, 428.1792; found, 428.1796.

(1R,5R)-9,9-Diethoxy-3-((4-fluorophenethyl)amino)-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(3i)
White solid; mp 181.3 °C; IR (KBr):
3421, 3188, 1719, 1619, 1511, 1382, 1079, 756 cm–1; 1H NMR (500 MHz, CDCl3): δ = 1.08–1.11
(m, 3H, CH3CH2O), 1.21–1.24 (m, 3H, CH3CH2O), 2.26–2.36 (m, 2H, COCH2, COCH2CHN), 2.67–2.71 (m, 1H, COCH2), 2.83–2.85 (m, 2H, CH2Ar), 2.87–2.88 (m,
1H, COCH2CHN), 3.43–3.50 (m, 4H, CH2N,
CH2O), 3.61–3.65 (m, 4H, CH2O), 3.66–3.70
(m, 1H, CH), 3.92–3.96 (m, 1H, CHN), 7.12–7.15 (m, 2H,
ArH), 7.28–7.31 (m, 2H, ArH), 8.05 (br, 1H, NH), 10.70 (br,
1H, NH); 13C NMR (125 MHz, CDCl3): δ =
15.5, 15.6, 33.5, 38.1, 41.5, 42.6, 46.4, 51.4, 56.5, 56.7, 96.2,
107.4, 115.6 (d, J = 21.3 Hz), 131.1 (d, J = 7.5 Hz), 134.9 (d, J = 2.5 Hz), 153.5,
161.5 (d, J = 240.0 Hz), 208.4; 13F NMR
(467 MHz, CDCl3): δ = −116.0; HRMS (EI+): m/z calcd for C20H27FN3O5 [M + H]+, 408.1929;
found, 408.1934.

(1R,5R)-3-((3-Chlorophenethyl)amino)-9,9-diethoxy-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(3j)
Yellow solid; mp 144.4 °C; IR (KBr):
3420, 3155, 1717, 1625, 1572, 1345, 1067, 756 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 1.07–1.10 (m, 3H, CH3CH2O), 1.19–1.22 (m, 3H, CH3CH2O), 2.35–2.38
(m, 1H, COCH2), 2.53–2.62 (m, 2H, COCH2, COCH2CHN), 2.75–2.83 (m, 3H, COCH2CHN, CH2Ar), 3.39–3.49 (m, 4H, CH2N,
CH2O), 3.56–3.60 (m, 2H, CH2O), 3.79–3.83
(m, 1H, CH), 3.91–3.95 (m, 1H, CHN), 7.03–7.05 (m, 1H,
ArH), 7.09–7.20 (m, 3H, ArH), 7.96 (br, 1H, NH), 10.89 (br,
1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 15.2, 15.2, 34.3, 37.9, 41.1, 42.4, 46.0, 51.6,
56.5, 56.6, 96.0, 108.1, 127.0, 127.2, 128.7, 130.1, 134.2, 140.0,
153.6, 208.3; HRMS (EI+): m/z calcd for C20H27ClN3O5 [M + H]+, 424.1634; found, 424.1637.

(1R,5R)-9,9-Diethoxy-4-nitro-3-(phenethylamino)-2-azabicyclo[3.3.1]non-3-en-7-one
(3k)
Yellow solid; mp 216.5–217.0 °C;
IR (KBr): 3441, 3146, 1717, 1627, 1569, 1345, 1066, 755 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 1.09–1.12 (m, 3H, CH3CH2O), 1.21–1.24 (m, 3H, CH3CH2O), 2.27–2.37
(m, 2H, COCH2, COCH2 CHN), 2.68–2.71
(m, 1H, COCH2), 2.84–2.89 (m, 3H, COCH2CHN, CH2Ar), 3.45–3.51 (m, 4H, CH2O,
CH2O), 3.61–3.65 (m, 2H, CH2N), 3.67–3.71
(m, 1H, CH), 3.93–3.97 (m, 1H, CHN), 7.22–7.33 (m, 5H,
ArH), 8.07 (br, 1H, NH), 10.71 (br, 1H, NH); 13C NMR (125
MHz, DMSO-d6): δ = 15.5, 15.6, 34.4,
38.1, 41.5, 42.6, 46.4, 51.4, 56.5, 56.7, 96.2, 107.4, 126.9, 128.9,
129.2, 138.8, 153.5, 208.4; HRMS (EI+): m/z calcd for C20H28N3O5 [M + H]+, 390.2023; found, 390.2025.

(1R,5R)-9,9-Diethoxy-4-nitro-3-((3-phenylpropyl)amino)-2-azabicyclo[3.3.1]non-3-en-7-one
(3l)
Yellow solid; mp 79.7 °C; IR (KBr):
3420, 1719, 1622, 1564, 1344, 1075, 753 cm–1; 1H NMR (500 MHz, DMSO-d6): δ
= 1.07–1.09 (m, 3H, CH3CH2O), 1.19–1.24
(m, 3H, CH3CH2O), 1.82–1.87 (m, 2H, CH2CH2N), 2.25–2.28 (m, 1H, COCH2), 2.49–2.50 (m, 2H, CH2Ar), 2.59–2.62 (m,
1H, COCH2), 2.68–2.72 (m, 1H, COCH2),
2.85–2.89 (m, 1H, COCH2CHN), 3.20–3.23 (m,
2H, CH2N), 3.45–3.50 (m, 2H, CH2O), 3.51–3.70
(m, 2H, CH2O), 3.69–3.73 (m, 1H, CH), 3.92–3.96
(m, 1H, CHN), 7.17–7.21 (m, 3H, ArH), 7.26–7.31 (m,
3H, ArH), 8.00 (br, 1H, NH), 10.81 (br, 1H, NH); 13C NMR
(125 MHz, DMSO-d6): δ = 15.3, 15.5,
30.2, 32.5, 38.2, 41.5, 46.4, 51.4, 56.5, 56.7, 96.2, 107.5, 126.4,
128.7, 128.9, 128.9, 141.4, 153.7, 208.4; HRMS (EI+): m/z calcd for C21H30N3O5 [M + H]+, 404.2180; found,
404.2185.

(1R,5R)-3-((4-Fluorobenzyl)amino)-4-nitro-2-azaspiro[bicyclo[3.3.1]nonane-9,2′-[1,3]dioxolan]-3-en-7-one
(3m)
White solid; mp 258.5–259.5 °C;
IR (KBr): 3429, 1726, 1629, 1567, 1339, 1056, 755 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 2.24–2.27 (m, 1H, COCH2), 2.42–2.4
(m, 1H, COCH2CHN), 2.88–2.98 (m, 2H, COCH2, COCH2CHN), 3.45–3.49 (m, 1H, CH), 3.67–3.71
(m, 1H, CHN), 4.00–4.08 (m, 2H, CH2O), 4.15–7.4.17
(m, 2H, CH2O), 4.49–4.50 (m, 2H, CH2N),
7.21–7.24 (m, 2H, ArH), 7.32–7.35 (m, 2H, ArH), 8.19
(br, H, NH), 10.95 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 40.5, 42.6, 44.0, 47.3, 53.8,
65.4, 65.8, 103.6, 107.3, 115.9 (d, J = 21.3 Hz),
129.8 (d, J = 8.9 Hz), 133.3 (d, J = 2.5 Hz), 153.1, 162.0 (d, J = 242.5 Hz), 208.0; 19F NMR (467 MHz, DMSO-d6): δ
= −115.0; HRMS (EI+): m/z calcd for C17H19FN3O5 [M + H]+, 364.1303; found, 364.1305.

(1R,5R)-3-(Benzylamino)-4-nitro-2-azaspiro[bicyclo[3.3.1]nonane-9,2′-[1,3]dioxolan]-3-en-7-one
(3n)
Yellow solid; mp 237.3–237.8 °C;
IR (KBr): 3419, 3250, 1720, 1619, 1558, 1381, 1254, 1053, 754 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 2.17–2.21 (m, 1H, COCH2), 2.36–2.43 (m, 1H, COCH2CHN), 2.81–2.90
(m, 2H, COCH2, COCH2CHN), 3.39–3.43 (m,
1H, CH), 3.60–3.64 (m, 1H, CHN), 3.93–4.01 (m, 2H, CH2O), 4.07–4.09 (m, 2H, CH2O), 4.43–4.44
(m, 2H, CH2N), 7.20–7.33 (m, 5H, ArH), 8.12 (br,
1H, NH), 10.90 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 40.4, 42.7, 44.7, 47.3, 53.8,
65.4, 65.8, 103.7, 107.3, 127.6, 128.1, 129.2, 137.0, 153.3, 207.9;
HRMS (EI+): m/z calcd
for C17H19N3O5 [M + H]+, 346.1397; found, 346.1398.

(1R,5R)-3-((3-Chlorophenethyl)amino)-4-nitro-2-azaspiro[bicyclo[3.3.1]nonane-9,2′-[1,3]dioxolan]-3-en-7-one
(3o)
Yellow solid; mp 188.8 °C; IR (KBr):
3442, 3253, 1723, 1623, 1564, 1393, 1258, 1065, 754 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 3.31–3.43 (m, 2H, COCH2, COCH2CHN), 2.83–2.91 (m, 3H, COCH2, CH2Ar), 2.91–2.98 (m, 1H, COCH2CHN), 3.41–3.50
(m, 3H, CH2N, CH2O), 3.68–3.72 (m, 1H,
CH), 4.00–4.07 (m, 2H, CH2O), 4.12–4.19 (m,
2H, CH2O, CHN), 7.23–7.40 (m, 4H, ArH), 8.09–8.10
(m, 1H, NH), 10.67–10.70 (m, 1H, NH); 13C NMR (125
MHz, DMSO-d6): δ = 33.9, 40.2, 42.4,
42.7, 47.3, 53.7, 65.3, 65.8, 103.7, 107.1, 127.0, 128.1, 129.2, 130.7,
133.5, 141.3, 153.1, 208.0; HRMS (EI+): m/z calcd for C18H21ClN3O5 [M + H]+, 394.1164; found, 394.1164.

(1R,5R)-4-Nitro-3-(phenethylamino)-2-azaspiro[bicyclo[3.3.1]nonane-9,2′-[1,3]dioxolan]-3-en-7-one
(3p)
Yellow solid; mp 221.8–222.3 °C;
IR (KBr): 3430, 3026, 1718, 1622, 1563, 1342, 1281, 1068, 754 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 2.31–2.34 (m, 1H, COCH2), 2.40–2.43 (m, 1H, COCH2CHN), 2.85–2.91
(m, 3H, COCH2, CH2Ar), 2.94–2.98 (m,
1H, COCH2CHN), 3.40–4.49 (m, 3H, CH2N,
CH), 3.67–3.71 (m, 1H, CHN), 4.00–4.07 (m, 2H, CH2O), 4.12–4.17 (m, 2H, CH2O), 7.23–7.34
(m, 5H, ArH), 8.09 (br, 1H, NH), 10.68 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 34.4,
42.7, 42.8, 47.3, 53.7, 65.3, 65.7, 103.7, 107.1, 127.0, 128.9, 129.3,
138.7, 153.1, 208.0; HRMS (EI+): m/z calcd for C18H22N3O5 [M + H]+, 360.1554; found, 360.1554.

(1R,5R,9R)-3-((4-Fluorobenzyl)amino)-9-methoxy-9-methyl-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(3q)
Yellow solid; mp 137.1 °C; IR (KBr):
3444, 1717, 1620, 1570, 1512, 1383, 1225, 1061, 754 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 1.60 (s, 3H, CH3), 2.20–2.24 (m, 1H,
COCH2), 2.36–2.40 (m, 1H, COCH2CHN),
2.75–2.80 (m, 1H, COCH2), 2.86–2.91 (m, 1H,
COCH2CHN), 3.06–3.10 (m, 3H, OCH3), 3.49–3.53
(m, 1H, CH), 3.78–3.82 (m, 1H, CHN), 4.47–4.50 (m, 2H,
CH2N), 7.19–7.23 (m, 2H, ArH), 7.29–7.32
(m, 2H, ArH), 7.98 (br, 1H, NH), 11.07 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 18.0,
40.2, 42.1, 43.6, 46.7, 49.3, 53.7, 71.5, 108.0, 115.8 (d, J = 21.4 Hz), 129.5 (d, J = 8.1 Hz), 133.5
(d, J = 2.8 Hz), 153.9, 161.9 (d, J = 241.8 Hz), 208.6; HRMS (EI+): m/z calcd for C17H21FN3O4 [M + H]+, 350.1511; found, 350.1513.

(1R,5R,9R)-3-(Benzylamino)-9-methoxy-9-methyl-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(3r)
Yellow solid; mp 126.9 °C; IR (KBr):
3260, 1718, 1620, 1564, 1433, 1346, 1200, 1059, 741 cm–1; 1H NMR (400 MHz, DMSO-d6): δ = 1.59–1.63 (s, 3H, CH3), 2.21–2.42
(m, 2H, COCH2, COCH2CHN), 2.80–2.91 (m,
2H, COCH2, COCH2CHN), 3.06–3.10 (m, 3H,
OCH3), 3.51–3.53 (m, 1H, CH), 3.79–3.83 (m,
1H, CHN), 4.50–4.52 (m, 2H, CH2N), 7.25–7.40
(m, 5H, ArH), 8.01 (br, 1H, NH), 11.11 (br, 1H, NH); 13C NMR (100 MHz, DMSO-d6): δ = 19.0,
40.2, 42.2, 44.4, 46.7, 49.3, 53.7, 71.5, 108.0, 127.8 (d, J = 10.2 Hz), 129.1, 137.2, 154.0, 208.6; HRMS (EI+): m/z calcd for C17H22N3O4 [M + H]+, 332.1605;
found, 332.1606.

(1R,5R,8S)-9,9-Dimethoxy-3-((4-methoxybenzyl)amino)-8-methyl-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(3s)
White solid; mp 254.8–255.8 °C;
IR (KBr): 3421, 3243, 1720, 1614, 1554, 1398, 1275, 1036, 756 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 0.74–0.76 (m, 3H, CH3),
2.35–2.38 (m, 1H, COCH2), 2.68–2.71 (m, 1H,
COCH2), 2.83–2.85 (m, 1H, COCH), 3.17 (s, 3H, OCH3), 3.36 (m, 3H, OCH3), 3.73–3.74 (m, 1H,
CH), 3.75–3.79 (m, 1H, CHN), 4.54–4.55 (m, 2H, CH2N), 7.21–7.23 (m, 2H, ArH), 7.29–7.32 (m, 1H,
ArH), 7.36–7.39 (m, 1H, ArH), 7.92 (br, 1H, NH), 11.05 (br,
1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 10.9, 38.4, 41.2, 44.4, 46.1, 48.7, 49.0, 55.4,
56.2, 96.9, 107.3, 127.3 (d, J = 16.3 Hz), 127.9,
129.1, 137.1, 153.9, 209.6; HRMS (EI+): m/z calcd for C19H26N3O6 [M + H]+, 392.1816; found, 392.1817.

(1R,5R,8S)-9,9-Dimethoxy-3-((4-methoxyphenethyl)amino)-8-methyl-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(3t)
Yellow solid; mp 171.3 °C; IR (KBr):
3445, 1717, 1623, 1563, 1514, 1349, 1247, 1081, 758 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 0.96–0.97 (s, 3H, CH3), 2.33–2.37
(m, 1H, COCH2), 2.69–2.70 (m, 2H, COCH2), 2.78–2.81 (m, 2H, CH2Ar), 2.85–2.88 (m,
1H, COCH), 3.17 (s, 3H, CH3O), 3.36 (s, 3H, CH3O), 3.71–3.74 (m, 2H, CH), 3.80–3.84 (m, 2H, CHN),
6.87–6.89 (m, 2H, ArH), 7.17–7.18 (m, 2H, ArH), 7.93
(br, 1H, NH), 10.70 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 11.2, 33.5, 38.3, 41.2, 43.0,
46.1, 48.7, 49.0, 55.5, 56.3, 96.8, 107.2, 114.3, 130.2, 130.6, 153.7,
158.5, 209.8; HRMS (EI+): m/z calcd for C20H28N3O6 [M + H]+, 406.1973; found, 406.1969.

(1R,5R,8S)-9,9-Dimethoxy-8-methyl-4-nitro-3-(phenethylamino)-2-azabicyclo[3.3.1]non-3-en-7-one
(3u)
White solid; mp 241.5–242.0 °C;
IR (KBr): 3425, 3260, 1718, 1623, 1563, 1348, 1274, 1079, 756 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 0.96–0.97 (s, 3H, CH3),
2.32–2.33 (m, 1H, COCH2), 2.68–2.72 (m, 1H,
COCH2), 2.84–2.86 (m, 2H, ArCH2), 2.89–2.91
(m, 1H, COCH), 3.17 (s, 3H, OCH3), 3.35 (s, 3H, OCH3), 3.45–3.48 (m, 2H, CH2N), 3.71 (s, 1H,
CH), 3.80 (s, 1H, CHN), 7.22–7.33 (m, 5H, ArH), 7.93 (br, 1H,
NH), 10.71 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 11.2, 34.4, 38.2, 41.2, 42.8,
46.1, 48.7, 49.0, 56.3, 96.8, 107.2, 127.0, 128.9, 129.2, 138.8, 153.7,
209.8; HRMS (EI+): m/z calcd for C19H26N3O5 [M + H]+, 376.1867; found, 376.1869.

(1R,5R)-3-((4-Fluorophenethyl)amino)-9,9-dimethoxy-1-methyl-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(3v)
Yellow solid; mp 241.5–242.0 °C;
IR (KBr): 3424, 3267, 1721, 1623, 1552, 1509, 1395, 1270, 1067, 756
cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 1.35–1.39 (m, 3H, CH3),
2.21–2.28 (m, 2H, COCH2), 2.72–2.76 (m, 1H,
COCH2CHN), 2.85–2.88 (m, 3H, COCH2CHN,
CH2Ar), 3.27 (s, 3H, OCH3), 3.45 (s, 3H, OCH3), 3.45–3.51 (m, 2H, CH2N), 3.84–3.88
(m, 1H, CH), 3.89–3.90 (m, 1H, CHN), 7.11–7.15 (m, 2H,
ArH), 7.30 (br, 2H, ArH), 7.57 (br, 1H, NH), 10.71 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ
= 21.6, 33.5, 37.3, 42.0, 42.8, 50.9, 51.2, 53.5, 61.8, 97.0, 107.0,
115.6 (d, J = 20.0 Hz), 131.1 (d, J = 8.8 Hz), 134.9 (d, J = 2.5 Hz), 153.0, 161.5
(d, J = 240.0 Hz), 208.0; HRMS (EI+): m/z calcd for C19H25FN3O5 [M + H]+, 394.1773; found,
394.1772.

(1R,5R)-9,9-Dimethoxy-1-methyl-3-((4-methylphenethyl)amino)-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(3w)
Yellow solid; mp 233.5–234.0 °C;
IR (KBr): 3440, 3276, 1718, 1625, 1560, 1513, 1359, 1060, 756 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 1.24–1.28 (m, 3H, CH3),
2.21–2.24 (m, 4H, CH3, COCH2), 2.50–2.53
(m, 1H, COCH2CHN), 2.63–2.67 (m, 2H, COCH2, COCH2CHN), 2.74–2.77 (m, 2H, CH2Ar),
3.24 (s, 3H, OCH3), 3.38–3.42 (m, 2H, CH2N), 3.39–3.43 (m, 1H, CH), 3.40 (s, 3H, OCH3),
3.98–3.99 (m, 1H, CHN), 5.99 (br, 1H, NH), 6.98–7.03
(m, 4H, ArH), 10.83 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 21.1, 21.8, 34.5, 37.1, 41.7,
43.1, 50.8, 51.2, 53.1, 61.6, 96.9, 107.6, 128.6, 129.7, 134.9, 136.4,
153.1, 207.9; HRMS (EI+): m/z calcd for C20H28N3O5 [M + H]+, 390.2023; found, 390.2024.

(1R,5R)-9,9-Dimethoxy-3-((4-methoxyphenethyl)amino)-1-methyl-4-nitro-2-azabicyclo-[3.3.1]non-3-en-7-one
(3x)
Yellow solid; mp 216.2–216.7 °C;
IR (KBr): 3424, 3278, 1718, 1625, 1556, 1514, 1360, 1245, 1074, 757
cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 1.36–1.40 (m, 3H, CH3),
2.21–2.28 (m, 2H, COCH2), 2.72–2.73 (m, 1H,
COCH2CHN), 2.76–2.81 (m, 2H, CH2Ar),
2.85–2.88 (m, 1H, COCH2CHN), 3.25–3.29 (m,
3H, CH3O), 3.45–3.46 (m, 3H, CH3O), 3.41–3.45
(m, 1H, CH), 3.71–3.75 (m, 3H, CH3O), 3.88–3.90
(m, 1H, CHN), 6.86–6.88 (m, 2H, ArH), 7.04 (br, 1H, NH), 7.17–7.19
(m, 2H, ArH), 10.70 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 21.6, 33.5, 37.3, 42.0, 43.1,
50.9, 51.2, 53.5, 55.5, 61.8, 97.0, 107.0, 114.3, 130.3, 130.6, 153.0,
158.5, 208.1; HRMS (EI+): m/z calcd for C20H28N3O6 [M + H]+, 406.1973; found, 406.1978.

(1R,5R)-3-((4-Chlorophenyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(3y)
Yellow solid; mp > 300 °C; IR (KBr):
3415, 1706, 1618, 1561, 1372, 1296, 1079, 760 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 2.22–2.25 (m, 1H, COCH2), 2.32–2.35
(m, 1H, COCH2), 2.65–2.68 (m, 1H, COCH2CH), 2.74–2.77 (m, 1H, COCH2CH), 3.12 (s, 3H, OCH3), 3.28 (s, 3H, OCH3), 3.70–43.71 (m, 1H,
CH), 3.81–3.85 (m, 1H, CHN), 7.22–7.24 (m, 2H, ArH),
7.46–7.48 (m, 2H, ArH), 7.89 (br, 1H, NH), 12.02 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ
= 37.4, 41.5, 45.9, 48.8, 49.0, 50.9, 96.4, 108.0, 127.8, 130.3, 131.8,
134.4, 152.6, 208.3; HRMS (EI+): m/z calcd for C16H18ClN3NaO5 [M + Na]+, 390.0827; found, 390.0833.

(1R,5R)-Ethyl 9,9-Dimethoxy-3-(methylamino)-7-oxo-2-azabicyclo[3.3.1]non-3-ene-4-carboxylate
(3z)
White solid; mp 184.2 °C; IR (KBr):
3432, 2977, 1638, 1542, 1450, 1320, 1158, 1065, 779 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 1.10–1.13 (m, 3H, CH3CH2O), 2.17–2.20 (m, 1H, COCH2), 2.34–2.37
(m, 1H, COCH2), 2.58–2.61 (m, 1H, COCH2CHN), 2.63–2.66 (m, 1H, COCH2CHN), 2.87 (s, 3H,
OCH3), 3.14 (s, 3H, CH3NH), 3.17–3.21
(m, 1H, CH), 3.32 (s, 3H, OCH3), 3.73–3.77 (m, 1H,
CHN), 3.89–3.98 (m, 2H, CH2O), 7.33 (br, 2H, NH,
NHCH3); 13C NMR (125 MHz, DMSO-d6): δ = 15.4, 34.7, 35.9, 43.0, 45.7, 48.5, 48.6,
57.6, 59.4, 72.5, 97.1, 157.9, 168.3, 210.0; HRMS (EI+): m/z calcd for C14H22NaN2O4 [M + Na]+, 321.1421; found,
321.1422.

(1R,5R)-Ethyl
9,9-Diethoxy-3-(methylamino)-7-oxo-2-azabicyclo[3.3.1]non-3-ene-4-carboxylate
(3a′)
White solid; mp 156.6 °C;
IR (KBr): 3472, 2974, 1640, 1537, 1441, 1320, 1164, 1069, 776 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 1.08–1.14 (m, 6H, CH3CH2O, CH3CH2O), 1.18–1.21 (m, 3H,
CH3CH2O), 2.18–2.21 (m, 1H, COCH2), 2.32–2.35 (m, 1H, COCH2), 2.58–2.65
(m, 1H, COCH2CHN), 2.67–2.68 (m, 1H, COCH2CH), 2.87 (s, 3H, CH3NH), 3.29–3.33 (m, 1H, CH),
3.45–3.48 (m, 2H, CH3CH2O), 3.55–3.59
(m, 2H, CH3CH2O), 3.73 (m, 1H, CHN), 3.89–3.99
(m, 2H, CH3CH2O), 7.35 (br, 2H, NH, NHCH3); 13C NMR (125 MHz, DMSO-d6): δ = 15.4, 15.6, 15.7, 35.6, 36.0, 43.2, 45.8, 56.2,
56.3, 57.6, 60.2, 72.8, 96.9, 158.0, 168.3, 210.0; HRMS (EI+): m/z calcd for C16H27N2O5 [M + H]+, 327.1914;
found, 327.1918.

(1R,5R)-Ethyl
3-Amino-9,9-dimethoxy-7-oxo-2-azabicyclo[3.3.1]non-3-ene-4-carboxylate
(3b′)
Yellow solid; mp 170.5 °C;
IR (KBr): 3414, 2959, 1638, 1537, 1372, 1086, 755 cm–1; 1H NMR (500 MHz, CDCl3): δ = 1.21–1.24
(m, 3H, CH3CH2O), 2.31–2.35 (m, 1H, COCH2), 2.42–2.45 (m, 1H, COCH2), 2.70–2.77
(m, 2H, COCH2CHN), 3.28 (s, 3H, OCH3), 3.34–3.38
(m, 1H, CH), 3.38 (s, 3H, OCH3), 3.77–3.81 (m, 1H,
CHN), 4.00–4.10 (m, 2H, CH2O), 5.57–5.58
(m, 1H, NH), 6.36 (br, 2H, NH2); 13C NMR (125
MHz, CDCl3): δ = 14.7, 34.4, 44.9, 46.7, 48.5, 48.6,
50.8, 58.4, 73.6, 97.3, 156.5, 169.1, 211.7; HRMS (EI+): m/z calcd for C13H19N2O5 [M – H]−, 283.1299;
found, 283.1303.

(1R,5R)-Ethyl
3-Amino-9,9-diethoxy-7-oxo-2-azabicyclo[3.3.1]non-3-ene-4-carboxylate
(3c′)
Yellow liquid; IR (KBr): 3413,
2976, 1639, 1538, 1372, 1083, 780 cm–1; 1H NMR (500 MHz, CDCl3): δ = 1.18–1.28 (m,
12H, CH3CH2O, CH3CH2O,
CH3), 2.33–2.36 (m, 1H, COCH2), 2.45–2.48
(m, 1H, COCH2), 2.73–2.80 (m, 2H, COCH2CHN), 3.34–3.38 (m, 1H, CH), 3.53–3.62 (m, 4H, CH2O, CH3CH2O), 3.75–3.79 (m, 1H,
CHN), 4.01–4.12 (m, 2H, CH3CH2O), 4.93
(br, 1H, NH), 6.15 (br, 2H, NH2); 13C NMR (125
MHz, CDCl3): δ = 14.8, 15.3, 15.3, 29.7, 35.0, 45.0,
46.9, 52.0, 56.4, 56.4, 58.5, 97.1, 156.0, 169.4, 211.8; HRMS (EI+): m/z calcd for C15H24N2NaO5 [M + Na]+,
335.1577; found, 335.1578.

General Procedure for the
Synthesis of Compounds 4
Quinone monoketals 1 (1.1 mmol), EDAMs 2 (1.0 mmol), Cs2CO3 (2.0 mmol), and
1,4-dioxane (15 mL) were charged into a 25 mL round-bottom flask.
The mixture was kept at reflux for about 6 h and monitored by TLC
until the quinone monoketal 1 substrate was completely
consumed. After the reaction was completed, the reaction system was
cooled to room temperature. The reaction mixture was poured into 25
mL of water and 50 mL of ethyl acetate for extraction and separation.
Then, the crude product was concentrated by distillation under reduced
pressure, purified by column chromatography (petroleum ether/ethyl
acetate = 2:1), and produced a series of compounds 4 in
a 65–89% yield.

(1R,5R)-2-(4-Fluorobenzyl)-3-((4-fluorobenzyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(4a)
Yellow solid; mp 158.6 °C; IR (KBr):
3409, 1714, 1585, 1511, 1474, 1358, 1223, 1087, 716 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 2.48–2.51 (m, 2H, COCH2), 2.75–2.78
(m, 2H, COCH2CHN), 3.12 (s, 3H, OCH3), 3.28
(s, 3H, OCH3), 3.79–3.80 (m, 1H, CH), 3.32–3.36
(m, 1H, CHN), 4.43–4.44 (m, 2H, CH2N), 4.76–4.78
(m, 2H, CH2N), 6.93–7.08 (m, 6H, ArH), 7.17–7.20
(m, 4H, ArH), 7.24–7.28 (m, 2H, ArH), 7.40–7.43 (m,
2H, ArH), 11.54 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 37.2, 41.2, 44.0, 48.8, 49.0,
49.1, 56.0, 59.4, 96.2, 111.2, 116.0, 116.1, 129.2 (d, J = 7.5 Hz), 129.7 (d, J = 7.5 Hz), 133.3 (d, J = 202.5 Hz), 133.3 (d, J = 202.5 Hz),
158.7, 162.1 (d, J = 242.5 Hz), 162.5 (d, J = 242.5 Hz), 207.4; 19F NMR (467 MHz, CDCl3): δ = −114.9, −114.5; HRMS (EI+): m/z calcd for C24H26FN3O5 [M + H]+, 474.1835;
found, 474.1836.

(1R,5R)-9,9-Dimethoxy-2-(4-methoxybenzyl)-3-((4-methoxybenzyl)amino)-4-nitro-2-aza-bicyclo[3.3.1]non-3-en-7-one
(4b)
Yellow solid; mp 74.8 °C; IR (KBr):
3421, 1717, 1613, 1513, 1461, 1351, 1250, 1094, 820 cm–1; 1H NMR (500 MHz, CDCl3): δ = 2.42–2.46
(m, 1H, COCH2), 2.54–2.56 (m, 1H, COCH2), 2.75–2.78 (m, 2H, COCH2CHN), 3.18 (s, 3H, OCH3), 3.22 (s, 3H, OCH3), 3.52–3.53 (m, 1H,
CH), 3.71 (s, 3H, CH3OAr), 3.75 (s, 3H, CH3OAr),
3.95–3.96 (m, 1H, CHN), 4.28–4.29 (m, 1H, CH2N), 4.34–4.36 (m, 1H, CH2N), 4.47–4.49 (m,
2H, CH2N), 6.76–6.78 (m, 2H, ArH), 6.85–6.87
(m, 2H, ArH), 6.96–6.97 (m, 2H, ArH), 7.13–7.20 (m,
2H, ArH), 11.62 (br, 1H, NH); 13C NMR (125 MHz, CDCl3): δ = 36.8, 41.0, 44.0, 48.7, 49.1, 49.3, 55.3, 55.4,
57.2, 58.2, 96.4, 111.3, 111.4, 114.6, 126.7, 127.9, 128.0, 128.8,
159.4, 159.5, 159.7, 207.1; HRMS (EI+): m/z calcd for C26H32N3O7 [M + H]+, 498.2235; found, 498.2239.

(1R,5R)-2-(2,4-Difluorobenzyl)-3-((2,4-difluorobenzyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(4c)
Yellow solid; mp 197.1 °C; IR (KBr):
3420, 1716, 1620, 1505, 1431, 1365, 1280, 1032, 773 cm–1; 1H NMR (500 MHz, CDCl3): δ = 2.46–2.49
(m, 1H, COCH2), 2.60–2.65 (m, 1H, COCH2CH), 2.73–2.77 (m, 2H, COCH2, COCH2CH),
3.15 (s, 3H, OCH3), 3.21 (s, 3H, OCH3), 3.51–3.55
(m, 1H, CH), 3.86–3.90 (m, 1H, CHN), 4.29–4.35 (m, 2H,
CH2N), 4.42–4.46 (m, 1H, CH2N), 4.67–4.71
(m, 1H, CH2N), 6.67–6.71 (m, 1H, ArH), 6.77–6.82
(m, 2H, ArH), 6.86–6.89 (m, 1H, ArH), 7.11–7.16 (m,
1H, ArH), 7.32–7.36 (m, 1H, ArH), 11.19 (m, 1H, NH); 13C NMR (125 MHz, CDCl3): δ = 36.6, 40.9, 43.7, 43.9,
48.7, 48.9, 51.8, 58.2, 96.1, 104.1–104.2 (m), 104.3–104.4
(m), 104.5–104.7 (m), 111.7–111.8 (m), 111.8, 111.8–112.0
(m), 118.4 (d, J = 17.5 Hz), 119.9 (d, J = 17.5 Hz), 129.1 (d, J = 13.8 Hz), 129.9 (d, J = 15.0 Hz), 159.4–159.8 (m), 160.1, 161.4–161.9
(m), 163.8–163.9 (m), 206.6; 19F NMR (467 MHz, CDCl3): δ = −113.9 (d, J = 4.7 Hz),
−112.4 (d, J = 4.7 Hz), −109.3 (d, J = 4.7 Hz), −109.2 (d, J = 4.7
Hz); HRMS (EI+): m/z calcd
for C24H24F4N3O5 [M + H]+, 510.1647; found, 510.1647.

(1R,5R)-2-(3,4-Difluorobenzyl)-3-((3,4-difluorobenzyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(4d)
Yellow solid; mp 178.2 °C; IR (KBr):
3420, 1720, 1581, 1519, 1434, 1347, 1298, 1039, 780 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 2.45–2.51 (m, 1H, COCH2), 2.75–2.80
(m, 2H, COCH2CH), 3.13 (s, 3H, OCH3), 3.28 (s,
3H, OCH3), 3.77–3.81 (m, 1H, CH), 3.87–3.91
(m, 2H, CHN), 4.41–4.42 (m, 2H, CH2N), 4.69–4.80
(m, 2H, CH2N), 6.97–7.01 (m, 1H, ArH), 7.17–7.20
(m, 2H, ArH), 7.38–7.49 (m, 3H, ArH), 11.34 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ
= 37.1, 41.2, 44.0, 48.4, 49.0, 49.1, 55.7, 59.6, 96.1, 111.4, 116.4–116.5
(m), 116.6–116.7 (m), 118.2, 118.3, 123.9, 124.3–124.4
(m), 134.1, 135.8, 148.2–148.4, 148.8–149.0, 150.2–150.4,
150.8–151.0, 158.8, 207.3; 19F NMR (467 MHz, DMSO-d6): δ = −140.3 (d, J = 23.4 Hz), −140.3 (d, J = 23.4 Hz), −138.0
(d, J = 18.7 Hz), −138.0 (d, J = 23.4 Hz); HRMS (EI+): m/z calcd for C24H24F4N3O5 [M + H]+, 510.1647; found, 510.1648.

(1R,5R)-2-(4-Fluorophenethyl)-3-((4-fluorophenethyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(4e)
Yellow solid; mp 140.8 °C; IR (KBr):
3419, 1713, 1618, 1579, 1468, 1351, 1229, 1066, 760 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 2.44–2.51 (m, 2H, COCH2), 2.71–2.75
(m, 1H, COCH2CH), 2.84–2.89 (m, 1H, COCH2CH), 2.91–2.96 (m, 2H, CH2Ar), 3.01–3.04
(m, 2H, CH2Ar), 3.18 (s, 3H, OCH3), 3.36 (s,
3H, OCH3), 3.46–3.50 (m, 1H, CH), 3.58–3.68
(m, 2H, CH2N), 3.69–4.13 (m, 2H, CH2N),
4.11–4.15 (m, 2H, CHN), 7.12–7.19 (m, 4H, ArH), 7.28–7.40
(m, 3H, ArH), 7.42–7.43 (m, 1H, ArH), 11.08 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ
= 27.3, 29.5, 37.2, 41.0, 44.8, 46.5, 49.1, 54.0, 58.7, 96.1, 110.8,
115.6–115.8 (m), 124.7–124.8 (m), 125.0–125.1
(m), 129.3–129.4 (m), 131.4–131.8 (m), 159.0, 161.1
(d, J = 241.3 Hz), 161.2 (d, J =
242.5 Hz), 207.5; 19F NMR (467 MHz, DMSO-d6): δ = −118.4, −118.3; HRMS (EI+): m/z calcd for C26H30F2N3O5 [M + H]+, 502.2148; found, 502.2149.

(1R,5R)-2-(3-Fluorophenethyl)-3-((3-fluorophenethyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(4f)
Yellow solid; mp 65.2 °C; IR (KBr):
3420, 2924, 1716, 1590, 1452, 1352, 1091, 782 cm–1; 1H NMR (500 MHz, CDCl3): δ = 2.33–2.36
(m, 1H, COCH2), 2.64–2.70 (m, 3H, COCH2, COCH2CH), 2.82–2.90 (m, 4H, CH2Ar),
3.14 (s, 3H, OCH3), 3.27 (s, 3H, OCH3), 3.36–3.39
(m, 1H, CH2N), 3.45–3.48 (m, 3H, CH2N,
CH2N), 3.59–3.63 (m, 1H, CH), 3.79–3.83 (m,
1H, CHN), 6.76–6.93 (m, 6H, ArH), 7.19–7.23 (m, 2H,
ArH), 11.07 (br, 1H, NH); 13C NMR (125 MHz, CDCl3): δ = 34.2, 36.2, 36.6, 40.8, 44.7, 48.7, 48.8, 49.0, 55.9,
59.1, 95.9, 111.2, 114.0–114.1 (m), 114.1–114.2 (m),
115.4, 115.5, 124.1–124.2 (m), 124.4, 130.4–130.5, 130.5–130.6,
139.5–139.6, 139.8–139.9, 159.6, 162.0, 164.0, 206.9; 19F NMR (467 MHz, CDCl3): δ = −112.6,
−112.2; HRMS (EI+): m/z calcd for C26H30F2N3O5 [M + H]+, 502.2148; found, 502.2149.

(1R,5R)-2-(2-Fluorophenethyl)-3-((2-fluorophenethyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(4g)
Yellow solid; mp 61.0 °C; IR (KBr):
3424, 1714, 1580, 1493, 1458, 1351, 1229, 1068, 759 cm–1; 1H NMR (500 MHz, CDCl3): δ = 2.38–2.41
(m, 1H, COCH2), 2.73–2.76 (m, 3H, COCH2, COCH2CHN), 2.94–2.98 (m, 4H, CH2Ar,
CH2Ar), 3.17 (s, 3H, OCH3), 3.33 (m, 3H, OCH3), 3.46–3.52 (m, 3H, CH2N, CH2N), 3.63–3.66 (m, 1H, CH2N), 3.70–3.74 (m,
1H, CH), 3.82–3.86 (m, 1H, CHN), 6.98–7.07 (m, 4H, ArH),
7.12–7.23 (m, 4H, ArH), 11.16 (br, 1H, NH); 13C
NMR (125 MHz, CDCl3): δ = 28.2, 30.5, 36.6, 40.7,
44.7, 47.1, 48.7, 48.9, 54.9, 58.8, 95.9, 111.1, 115.5, 115.7, 123.8,
124.0, 124.5, 124.6, 129.0, 129.2, 131.3, 131.3, 159.6, 161.1 (d, J = 243.8 Hz), 161.1 (d, J = 243.8 Hz),
206.9; HRMS (EI+): m/z calcd for C26H30F2N3O5 [M + H]+, 502.2148; found, 502.2149.

(1R,5R)-2-(4-Chlorophenethyl)-3-((4-chlorophenethyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(4h)
Yellow solid; mp 168.5 °C; IR (KBr):
3414, 1717, 1589, 1494, 1355, 1039, 775 cm–1; 1H NMR (500 MHz, CDCl3): δ = 2.33–2.36
(m, 1H, COCH2), 2.64–2.65 (m, 1H, COCH2CH), 2.69–2.71 (m, 2H, COCH2, COCH2CH),
2.81–2.88 (m, 4H, CH2Ar), 3.13 (s, 3H, OCH3), 3.28 (s, 3H, OCH3), 3.33–3.37 (m, 1H, CH2N), 3.41–3.47 (m, 1H, CH2N), 3.56–3.60
(m, 1H, CH), 3.79–3.83 (m, 1H, CHN), 6.98–6.99 (m, 2H,
ArH), 7.06–7.08 (m, 2H, ArH), 7.20–7.22 (m, 4H, ArH),
11.05 (br, 1H, NH); 13C NMR (125 MHz, CDCl3):
δ = 33.9, 35.8, 36.6, 40.8, 44.8, 48.7, 49.0, 49.0, 56.0, 59.2,
95.9, 111.1, 129.0, 129.1, 129.8, 130.0, 133.2, 133.1, 135.5, 135.9,
159.6, 206.8; HRMS (EI+): m/z calcd for C26H30Cl2N3O5 [M + H]+, 534.1557; found, 534.1561.

(1R,5R)-2-(3-Chlorophenethyl)-3-((3-chlorophenethyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(4i)
Yellow solid; mp 74.5 °C; IR (KBr):3422,
1716, 1599, 1465, 1351, 1075, 782 cm–1; 1H NMR (500 MHz, CDCl3): δ = 2.38–2.42 (m,
1H, COCH2), 2.71–2.77 (m, 3H, COCH2,
COCH2CHN), 2.87–2.95 (m, 4H, CH2Ar, CH2Ar), 3.20 (s, 3H, OCH3), 3.34 (s, 3H, OCH3), 3.41–3.44 (m, 1H, CH2N), 3.51–3.55 (m,
2H, CH2N), 3.67–3.71 (m, 1H, CH2N), 3.67–3.71
(m, 1H, CH), 3.86–3.87 (m, 1H, CHN), 7.00–7.24 (m, 8H,
ArH), 11.13 (br, 1H, NH); 13C NMR (125 MHz, CDCl3): δ = 34.1, 36.1, 36.6, 40.8, 44.7, 48.7, 48.8, 49.0, 55.8,
59.1, 95.9, 111.2, 126.7, 127.0, 127.3, 127.4, 128.6, 128.6, 130.2,
130.3, 134.5, 134.7, 139.1, 139.5, 159.6, 206.9; HRMS (EI+): m/z calcd for C26H30Cl2N3O5 [M + H]+, 534.1557; found, 534.1559.

(1R,5R)-2-(2-Chlorophenethyl)-3-((2-chlorophenethyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(4j)
Yellow solid; mp 124.1 °C; IR (KBr):
3422, 1715, 1575, 1465, 1349, 1094, 759 cm–1; 1H NMR (500 MHz, CDCl3): δ = 2.44–2.51
(m, 2H, COCH2), 2.72–2.76 (m, 1H, COCH2CHN), 2.87–2.91 (m, 1H, COCH2CHN), 3.00–3.03
(m, 2H, CH2Ar), 3.09–3.12 (m, 2H, CH2Ar), 3.19 (s, 3H, OCH3), 3.37 (s, 3H, OCH3),
3.43–3.47 (m, 1H, CH2N), 3.54–3.61 (m, 2H,
CH2N), 3.68–3.69 (m, 1H, CH), 3.72–3.75 (m,
1H, CH2N), 4.11–4.15 (m, 1H, CHN), 7.25–7.32
(m, 4H, ArH), 7.35–7.36 (m, 1H, ArH), 7.39–7.41 (m,
1H, ArH), 7.44–7.48 (m, 1H, ArH), 11.06 (br, 1H, NH); 13C NMR (125 MHz, CDCl3): δ = 31.4, 34.1,
37.2, 41.0, 44.9, 46.5, 49.1, 49.2, 54.1, 58.4, 96.1, 110.9, 127.8,
128.0, 129.2, 129.2, 129.9, 131.4, 131.8, 133.5, 133.6, 135.6, 135.7,
137.4, 159.2, 207.3; HRMS (EI+): m/z calcd for C26H30Cl2N3O5 [M + H]+, 534.1557; found, 534.1557.

(1R,5R)-9,9-Dimethoxy-4-nitro-2-phenethyl-3-(phenethylamino)-2-azabicyclo[3.3.1]non-3-en-7-one
(4k)
Yellow liquid; IR (KBr): 3421, 1716, 1587,
1455, 1352, 1262, 1069, 700 cm–1; 1H
NMR (500 MHz, CDCl3): δ = 2.29–2.32 (m, 1H,
COCH2), 2.59–2.67 (m, 3H, COCH2, COCH2CH), 2.79–2.85 (m, 4H, CH2Ar, CH2Ar), 3.09 (s, 3H, OCH3), 3.22 (s, 3H, OCH3),
3.36–3.50 (m, 4H, CH2N), 3.59–3.63 (m, 1H,
CH), 3.76–3.80 (m, 1H, CHN), 7.02–7.04 (m, 2H, ArH),
7.10–7.20 (m, 8H, ArH), 11.15 (br, 1H, NH); 13C
NMR (125 MHz, CDCl3): δ = 34.6, 36.5, 36.7, 40.8,
44.7, 48.7, 48.9, 49.1, 56.2, 59.0, 95.9, 111.0, 127.0, 127.2, 128.5,
128.7, 128.8, 129.0, 137.1, 137.5, 159.6, 207.1; HRMS (EI+): m/z calcd for C26H32N3O5 [M + H]+, 466.2336;
found, 466.2339.

(1R,5R)-9,9-Dimethoxy-2-(4-methylphenethyl)-3-((4-methylphenethyl)amino)-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(4l)
Yellow liquid; IR (KBr): 3472, 1717, 1591,
1461, 1350, 1261, 1092, 716 cm–1; 1H
NMR (500 MHz, CDCl3): δ = 2.24 (s, 6H, CH3Ar), 2.29–2.32 (m, 1H, COCH2), 2.59–2.61
(m, 1H, COCH2), 2.68–2.71 (m, 1H, COCH2CH), 2.80–2.86 (m, 4H, CH2Ar, CH2Ar),
3.12 (s, 3H, OCH3), 3.25 (s, 3H, OCH3), 3.38–3.54
(m, 4H, CH2N, CH2N), 3.54–3.55 (m, 1H,
CH), 3.80–3.81 (m, 1H, CHN), 6.93–7.05 (m, 8H, ArH),
11.15 (br, 1H, NH); 13C NMR (125 MHz, CDCl3):
δ = 21.1, 21.1, 34.2, 36.1, 36.6, 40.8, 44.7, 48.7, 49.0, 49.3,
56.5, 58.9, 96.1, 111.0, 128.4, 128.6, 129.5, 129.5, 129.6, 129.6,
133.9, 134.4, 136.7, 136.9, 159.6, 207.0; HRMS (EI+): m/z calcd for C28H36N3O5 [M + H]+, 494.2649; found,
494.2651.

(1R,5R)-9,9-Dimethoxy-4-nitro-2-(3-phenylpropyl)-3-((3-phenylpropyl)amino)-2-azabicyclo[3.3.1]non-3-en-7-one
(4m)
Yellow solid; mp 163.8 °C; IR (KBr):
3417, 1716, 1603, 1561, 1453, 1350, 1201, 1054, 752 cm–1; 1H NMR (500 MHz, DMSO): δ = 1.68–1.74 (m,
3H, CH2CH2N, COCH2), 1.93–1.97
(m, 1H, COCH2), 2.34–2.37 (m, 1H, COCH2CH), 2.47–2.58 (m, 6H, CH2Ar, CH2Ar,
CH2CH2N), 2.71–2.75 (m, 2H, CH2N), 2.83–2.87 (m, 2H, CH2N), 2.93–2.97 (m,
1H, COCH2CH), 2.85–2.89 (m, 1H, CH2Ar),
3.16 (s, 3H, OCH3), 3.31 (s, 3H, OCH3), 3.68–3.72
(m, 1H, CH), 3.98–4.02 (m, 1H, CHN), 7.12–7.30 (m, 10H,
ArH), 11.19 (br, 1H, NH); 13C NMR (125 MHz, CDCl3): δ = 29.6, 31.7, 32.1, 32.3, 37.4, 41.0, 44.9, 45.7, 49.1,
53.2, 58.7, 96.1, 110.4, 126.5, 128.8, 128.8, 128.8, 128.9, 128.9,
128.9, 128.9, 141.1 (d, J = 20.0 Hz), 158.8, 207.6;
HRMS (EI+): m/z calcd
for C28H36N3O5 [M + H]+, 494.2649; found, 494.2652.

(1R,5R)-2-Benzyl-3-(benzylamino)-9,9-diethoxy-4-nitro-2-azabicyclo[3.3.1]non-3-en-7-one
(4n)
Yellow liquid; IR (KBr): 3423, 1716, 1592,
1453, 1351, 1075, 733 cm–1; 1H NMR (500
MHz, CDCl3): δ = 1.11–1.14 (m, 6H, CH3CH2O, CH3CH2O), 2.46–2.50
(m, 1H, COCH2), 2.56–2.57 (m, 1H, COCH2CHN), 2.78–2.80 (m, 2H, COCH2, COCH2CHN), 3.29–3.33 (m, 1H, CH2O), 3.44–3.48
(m, 2H, CH2O), 3.55–3.56 (m, 1H, CH2O),
3.97–3.98 (m, 1H, CH2O), 4.30–4.36 (m, 2H,
CH2N), 4.46–4.50 (m, 1H, CH), 4.48–4.52 (m,
1H, CHN), 6.98–7.73 (m, 10H, ArH), 11.78 (br, 1H, NH); 13C NMR (125 MHz, CDCl3): δ = 15.1, 15.2,
37.5, 41.1, 43.9, 49.5, 56.7, 56.9, 57.4, 59.5, 96.0, 111.5, 126.4,
126.6, 128.0, 128.2, 129.0, 129.2, 135.2, 136.8, 159.8, 207.3; HRMS
(EI+): m/z calcd for
C26H32N3O5 [M + H]+, 466.2336; found, 466.2341.

(1R,5R)-2-(4-Methoxybenzyl)-3-((4-methoxybenzyl)amino)-4-nitro-2-azaspiro[bicyclo[3.3.1]nonane-9,2′-[1,3]dioxolan]-3-en-7-one
(4o)
Yellow solid; mp 164.1 °C; IR (KBr):
3417, 1719, 1614, 1547, 1355, 1276, 1028, 712 cm–1; 1H NMR (400 MHz, DMSO-d6): δ = 2.50–2.62 (m, 2H, COCH2, COCH2CH), 2.85–2.93 (m, 2H, COCH2, COCH2CH), 3.38–3.42 (m, 1H, CH2O), 3.54–3.58
(m, 1H, CH2O), 3.74 (s, 3H, OCH3), 3.76 (s,
3H, OCH3), 4.00–4.11 (m, 3H, CH2O, CH2N), 4.42–4.43 (m, 2H, CH2N), 4.62–4.76
(s, 2H, CH, CHN), 6.90–6.92 (m, 2H, ArH), 6.98–7.00
(m, 2H, ArH), 7.10–7.12 (m, 2H, ArH), 7.30–7.32 (m,
2H, ArH), 11.8 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 40.6, 40.8, 42.1, 49.4, 55.4,
55.6, 56.4, 59.7, 65.4, 65.7, 103.4, 111.1, 114.7, 114.7, 128.0, 128.9,
129.1, 129.7, 158.7, 159.3, 159.3, 207.0; HRMS (EI+): m/z calcd for C26H30N3O7 [M + H]+, 496.2078; found,
496.2078.

(5R,9R)-10-Benzoyl-11,11-dimethoxy-2,3,5,6,8,9-hexahydro-7H-5,9-methanooxazolo[3,2-a]azocin-7-one
(6a)
Yellow liquid; IR (KBr): 3415, 2959, 1714,
1528, 1405, 1285, 1113, 1070, 745 cm–1; 1H NMR (500 MHz, CDCl3): δ = 2.54–2.57 (m,
2H, COCH2), 2.76–2.80 (m, 1H, COCH2CHN),
2.87–2.91 (m, 1H, COCH2CHN), 3.30 (s, 3H, CH3O), 3.39–3.41 (m, 1H, CH), 3.44 (s, 3H, CH3O), 3.55–3.60 (m, 1H, CHN), 3.83–3.87 (m, 2H, CH2N), 4.16–4.23 (m, 2H, CH2O), 7.27–7.32
(m, 3H, ArH), 7.36–7.38 (m, 2H, ArH); 13C NMR (125
MHz, CDCl3): δ = 34.6, 42.6, 44.7, 46.6, 49.0, 49.0,
55.7, 67.6, 87.4, 97.9, 127.3, 127.5, 129.0, 143.2, 162.1, 190.0,
209.2; HRMS (EI+): m/z calcd for C19H22NO5 [M + H]+, 344.1492; found, 344.1488.

(5R,9R)-10-Benzoyl-11,11-diethoxy-2,3,5,6,8,9-hexahydro-7H-5,9-methanooxazolo[3,2-a]azocin-7-one
(6b)
Yellow solid; mp 199.4 °C; IR (KBr):
3416, 2974, 1719, 1542, 1454, 1226, 1116, 1070, 745 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 1.12–1.15 (m, 3H, C3CH2O), 1.23–1.26 (m, 3H, C3CH2O), 2.20–2.23
(m, 1H, COCH2), 2.52–2.55 (m, 1H, COCH2), 2.74–2.82 (m, 2H, COCH2CHN), 3.41–3.45
(m, 1H, CH), 3.48–3.57 (m, 3H, CH2N, C3CH2O), 3.62–3.70 (m, 3H, C3CH2O), 3.09–4.13 (m, 1H, CHN), 4.18–4.23 (m, 2H, CH2O), 7.20–7.22 (m, 2H, ArH), 7.27–7.34 (m, 3H,
ArH); 13C NMR (125 MHz, DMSO-d6): δ = 15.7, 15.8, 35.7, 42.8, 45.1, 46.3, 55.4, 56.6, 56.9,
68.4, 86.8, 97.9, 127.7, 127.7, 129.2, 144.0, 162.3, 188.3, 209.4;
HRMS (EI+): m/z calcd
for C21H26NO5 [M + H]+, 372.1805; found, 372.1802.

(5R,9R)-10-Benzoyl-11,11-dimethoxy-2,3,5,6,8,9-hexahydro-7H-5,9-methanothiazolo[3,2-a]azocin-7-one
(6c)
Yellow liquid; IR (KBr): 3440, 2956, 1715,
1593, 1496, 1407, 1246, 1115, 1061, 750 cm–1; 1H NMR (500 MHz, CDCl3): δ = 2.20–2.23
(m, 1H, COCH2), 2.45–2.49 (m, 1H, COCH2), 2.58–2.64 (m, 2H, COCH2CHN), 2.92–2.98
(m, 2H, CH2S), 3.16 (s, 3H, OCH3), 3.25 (s,
3H, OCH3), 3.27–3.31 (m, 1H, CH), 3.46–3.49
(m, 1H, CH2N), 3.62–3.65 (m, 1H, CH2N),
3.79–3.83 (m, 1H, CHN), 7.24–7.29 (m, 5H, ArH); 13C NMR (125 MHz, CDCl3): δ = 27.9, 36.4,
41.7, 45.5, 48.8, 48.9, 53.0, 57.0, 97.5, 102.0, 126.4, 128.2, 129.0,
141.3, 161.3, 190.7, 208.4; HRMS (EI+): m/z calcd for C19H22NO4S [M + H]+, 360.1264; found, 360.1265.

Supporting Information Available
The Supporting Information
is
available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.7b01493.Spectroscopic
and analytical data and the original copy
of 1H and 13C NMR spectra of all new compounds
(PDF)

X-ray
crystallographic data of compound 3b (CCDC 1546771) (CIF)

X-ray crystallographic
data of compound 3e (CCDC 1546772) (CIF)

X-ray crystallographic data
of compound 3u (CCDC 1578670) (CIF)

X-ray crystallographic data of compound 4a (CCDC 1546773) (CIF)



Supplementary Material
ao7b01493_si_001.pdf

 ao7b01493_si_002.cif

 ao7b01493_si_003.cif

 ao7b01493_si_004.cif

 ao7b01493_si_005.cif

 The authors
declare no competing financial interest.

Acknowledgments
This work was supported
by the Program for Changjiang
Scholars and Innovative Research Team in University (no. IRT17R94),
the National Natural Science Foundation of China (nos. 21662042, 21362042,
81760621, and U1202221), the Natural Science Foundation of Yunnan
Province (2017FA003), the Reserve Talent Foundation of Yunnan Province
for Middle-aged and Young Academic and Technical Leaders (no. 2012HB001),
Donglu Scholars of Yunnan University, Excellent Young Talents, Yunnan
University, and High-Level Talents Introduction Plan of Yunnan Province.
==== Refs
References
Bradshaw B. ; Parra C. ; Bonjoch J. 
Organocatalyzed Asymmetric Synthesis
of Morphans . Org. Lett. 
2013 , 15 , 2458 –2461 . 10.1021/ol400926p .23627688 
Cronyn M. W. ; Riesser G. H. 
Azabicycloalkanes. II. 1,5-Substituted Morphan . J. Am. Chem. Soc. 
1953 , 75 , 1664 –1668 . 10.1021/ja01103a043 .
Huo H.-H. ; Xia X.-E. ; Zhang H.-K. ; Huang P.-Q. 
Enantioselective
Total Syntheses of (−)-FR901483 and (+)-8-epi-FR901483 . J. Org. Chem. 
2013 , 78 , 455 –465 . 10.1021/jo302362b .23214918 
Yao Y. ; Liang G. 
Rapid Construction
of the ABC Ring System in the Daphniphyllum Alkaloid
Daphniyunnine C . Org. Lett. 
2012 , 14 , 5499 –5501 . 10.1021/ol3026395 .23095081 
Carroll F. I. ; Gichinga M. G. ; Williams J. D. ; Vardy E. ; Roth B. L. ; Mascarella S. W. ; Thomas J. B. ; Navarro H. A. 
4β-Methyl-5-(3-hydroxyphenyl)morphan
Opioid Agonist and Partial Agonist Derived from a 4β-Methyl-5-(3-hydroxyphenyl)morphan
Pure Antagonist . J. Med. Chem. 
2013 , 56 , 8826 –8833 . 10.1021/jm401250s .24144404 
a Gates M. ; Montzka T. A. 
Some Potent Morphine Antagonists
Possessing High Analgesic Activity . J. Med.
Chem. 
1964 , 7 , 127 –131 . 10.1021/jm00332a002 .14187361  b Kieffer B. L. 
Drug discovery: Designing the ideal opioid . Nature 
2016 , 537 , 170 –171 . 10.1038/nature19424 .27533037 
Carroll F. I. ; Melvin M. S. ; Nuckols M. C. ; Mascarella S. W. ; Navarro H. A. ; Thomas J. B. 
N-Substituted 4β-Methyl-5-(3-hydroxyphenyl)-7α-amidomorphans
Are Potent, Selective κ Opioid Receptor Antagonists . J. Med. Chem. 
2006 , 49 , 1781 –1791 . 10.1021/jm058264p .16509593 
Iijima I. ; Minamikawa J. ; Jacobson A. E. ; Brossi A. ; Rice K. C. ; Klee W. A. 
Studies
in the (+)-morphinan series. 5. Synthesis and
biological properties of (+)-naloxone . J. Med.
Chem. 
1978 , 21 , 398 –400 . 10.1021/jm00202a018 .206698 
Selfridge B. R. ; Wang X. ; Zhang Y. ; Yin H. ; Grace P. M. ; Watkins L. R. ; Jacobson A. E. ; Rice K. C. 
Structure–Activity
Relationships of (+)-Naltrexone-Inspired Toll-like Receptor 4 (TLR4)
Antagonists . J. Med. Chem. 
2015 , 58 , 5038 –5052 . 10.1021/acs.jmedchem.5b00426 .26010811 
Botros S. ; Lipkowski A. W. ; Takemori A. E. ; Portoghese P. S. 
Investigation
of the structural requirements for the κ-selective opioid receptor
antagonist 6β,6β′-[ethylenebis(oxyethyleneimino)]bis[17-(cyclopropylmethyl)-4,5α-epoxymorphinan-3,14-diol](TENA) . J. Med. Chem. 
1986 , 29 , 874 –876 . 10.1021/jm00155a048 .3009817 
Black S. L. ; Chauvignac C. ; Grundt P. ; Miller C. N. ; Wood S. ; Traynor J. R. ; Lewis J. W. ; Husbands S. M. 
Guanidino N-Substituted
and N,N-Disubstituted
Derivatives of the κ-Opioid Antagonist GNTI . J. Med. Chem. 
2003 , 46 , 5505 –5511 . 10.1021/jm0309203 .14640558 
Korlipara V. L. ; Takemori A. E. ; Portoghese P. S. 
N-Benzylnaltrindoles
as Long-Acting δ-Opioid Receptor Antagonists . J. Med. Chem. 
1994 , 37 , 1882 –1885 . 10.1021/jm00038a018 .8021928 
Todtenkopf M. S. ; Marcus J. F. ; Portoghese P. S. ; Carlezon W. A. Jr.
Effects of κ-opioid receptor ligands on intracranial self-stimulation
in rats . Psychopharmacology 
2004 , 172 , 463 –470 . 10.1007/s00213-003-1680-y .14727002 
Comer S. D. ; Burke T. F. ; Lewis J. W. ; Woods J. H. 
Clocinnamox:
a novel,
systemically-active, irreversible opioid antagonist . J. Pharmacol. Exp. Ther. 
1992 , 262 , 1051 –1056 .1326622 
Quirante J. ; Paloma L. ; Diaba F. ; Vila X. ; Bonjoch J. 
Synthesis
of Diazatricyclic Core of Madangamines from cis-Perhydroisoquinolines . J. Org. Chem. 
2008 , 73 , 768 –771 . 10.1021/jo702340w .18095709 
Ananthan S. ; Kezar H. S. III; Carter R. L. ; Saini S. K. ; Rice K. C. ; Wells J. L. ; Davis P. ; Xu H. ; Dersch C. M. ; Bilsky E. J. ; Porreca F. ; Rothman R. B. 
Synthesis,
Opioid Receptor Binding, and Biological Activities of Naltrexone-Derived
Pyrido- and Pyrimidomorphinans . J. Med. Chem. 
1999 , 42 , 3527 –3538 . 10.1021/jm990039i .10479286 
Liu R.-R. ; Li B.-L. ; Lu J. ; Shen C. ; Gao J.-R. ; Jia Y.-X. 
Palladium/L-Proline-Catalyzed Enantioselective α-Arylative
Desymmetrization of Cyclohexanones . J. Am. Chem.
Soc. 
2016 , 138 , 5198 –5201 . 10.1021/jacs.6b01214 .27078124 
a Wang Y.-F. ; Toh K. K. ; Ng E. P. J. ; Chiba S. 
Mn(III)-Mediated Formal [3+3]-Annulation of Vinyl Azides
and Cyclopropanols: A Divergent Synthesis of Azaheterocycles . J. Am. Chem. Soc. 
2011 , 133 , 6411 –6421 . 10.1021/ja200879w .21449592  b Wang Y.-F. ; Chiba S. 
Mn(III)-Mediated Reactions
of Cyclopropanols with Vinyl Azides: Synthesis of Pyridine and 2-Azabicyclo[3.3.1]non-2-en-1-ol
Derivatives . J. Am. Chem. Soc. 
2009 , 131 , 12570 –12572 . 10.1021/ja905110c .19722716 
Rouden J. ; Lasne M.-C. ; Blanchet J. ; Baudoux J. 
(−)-Cytisine
and Derivatives: Synthesis, Reactivity, and Applications . Chem. Rev. 
2014 , 114 , 712 –778 . 10.1021/cr400307e .24117010 
a Diaba F. ; Martínez-Laporta A. ; Bonjoch J. ; Pereira A. ; Muñoz-Molina J. M. ; Pérez P. J. ; Belderrain T. R. 
Cu(I)-catalyzed atom transfer radical
cyclization of trichloroacetamides tethered to electron-deficient,
-neutral, and -rich alkenes: synthesis of polyfunctionalized 2-azabicyclo[3.3.1]nonanes . Chem. Commun. 
2012 , 48 , 8799 –8801 . 10.1039/c2cc34133f . b Diaba F. ; Martínez-Laporta A. ; Bonjoch J. 
Atom Transfer Radical Cyclization of Trichloroacetamides
to Electron-Rich Acceptors Using Grubbs’ Catalysts: Synthesis
of the Tricyclic Framework of FR901483 . J. Org.
Chem. 
2014 , 79 , 9365 –9372 . 10.1021/jo501110c .25203675 
Puppala M. ; Murali A. ; Baskaran S. 
Concise enantioselective
construction
of a bridged azatricyclic framework via domino semipinacol–Schmidt
reaction . Chem. Commun. 
2012 , 48 , 5778 –5780 . 10.1039/c2cc31906c .
a Tamura Y. ; Yakura T. ; Haruta J. ; Kita Y. 
Hypervalent
iodine oxidation of p-alkoxyphenols
and related compounds: a general route to p-benzoquinone
monoacetals and spiro lactones . J. Org. Chem. 
1987 , 52 , 3927 –3930 . 10.1021/jo00226a041 . b Pelter A. ; Elgendy S. 
Phenolic oxidation with (diacetoxyiodo)benzene . Tetrahedron Lett. 
1988 , 29 , 677 –680 . 10.1016/s0040-4039(00)80182-3 .
Reviews see:

a Wu W.-T. ; Zhang L. ; You S.-L. 
Catalytic
asymmetric dearomatization (CADA) reactions of phenol and aniline
derivatives . Chem. Soc. Rev. 
2016 , 45 , 1570 –1580 . 10.1039/c5cs00356c .26796922  b Yang X. ; Wang J. ; Li P. 
Recent progress on
asymmetric organocatalytic construction of chiral cyclohexenone skeletons . Org. Biomol. Chem. 
2014 , 12 , 2499 –2513 . 10.1039/c3ob42293c .24599029  c Sridhar M. ; Mallu K. ; Jillella R. ; Godala K. ; Beeram C. ; Chinthala N. 
One-Step Synthesis
of 5-Substituted 1H-Tetrazoles from an Aldehyde by Reaction with Acetohydroxamic
Acid and Sodium Azide under Bi(OTf)3 Catalysis . Synthesis 
2013 , 45 , 507 –510 . 10.1055/s-0032-1318108 .
a Bos P. H. ; Antalek M. T. ; Porco J. A. Jr.; Stephenson C. R. J. 
Tandem Dienone Photorearrangement–Cycloaddition
for the Rapid Generation of Molecular Complexity . J. Am. Chem. Soc. 
2013 , 135 , 17978 –17982 . 10.1021/ja409992m .24161069  b Liu P. ; Fukui Y. ; Tian P. ; He Z.-T. ; Sun C.-Y. ; Wu N.-Y. ; Lin G.-Q. 
Cu-Catalyzed Asymmetric
Borylative Cyclization of Cyclohexadienone-Containing 1,6-Enynes . J. Am. Chem. Soc. 
2013 , 135 , 11700 –11703 . 10.1021/ja404593c .23899092 
a Nicolaou K. C. ; Hale C. R. H. ; Nilewski C. ; Ioannidou H. A. ; Elmarrouni A. ; Nilewski L. G. ; Beabout K. ; Wang T. T. ; Shamoo Y. 
Total Synthesis of Viridicatumtoxin
B and Analogues Thereof: Strategy Evolution, Structural Revision,
and Biological Evaluation . J. Am. Chem. Soc. 
2014 , 136 , 12137 –12160 . 10.1021/ja506472u .25317739  b Guo F. ; Konkol L. C. ; Thomson R. J. 
Enantioselective Synthesis of Biphenols
from 1,4-Diketones by Traceless Central-to-Axial Chirality Exchange . J. Am. Chem. Soc. 
2011 , 133 , 18 –20 . 10.1021/ja108717r .21141997 
a Konkol L. C. ; Guo F. ; Sarjeant A. A. ; Thomson R. J. 
Enantioselective Total Synthesis and Studies into the
Configurational Stability of Bismurrayaquinone A . Angew. Chem., Int. Ed. 
2011 , 50 , 9931 –9934 . 10.1002/anie.201104726 . b Dohi T. ; Washimi N. ; Kamitanaka T. ; Fukushima K.-i. ; Kita Y. 
Coupling of Quinone
Monoacetals Promoted by Sandwiched Brønsted Acids: Synthesis
of Oxygenated Biaryls . Angew. Chem., Int. Ed. 
2011 , 50 , 6142 –6146 . 10.1002/anie.201101646 .
a Yin Z. ; Zhang J. ; Wu J. ; Liu C. ; Sioson K. ; Devany M. ; Hu C. ; Zheng S. 
Double Hetero-Michael
Addition of N-Substituted Hydroxylamines to Quinone
Monoketals: Synthesis of Bridged Isoxazolidines . Org. Lett. 
2013 , 15 , 3534 –3537 . 10.1021/ol401235z .23829680  b Yin Z. ; Zhang J. ; Wu J. ; Green R. ; Li S. ; Zheng S. 
Synthesis of o-chlorophenols via an
unexpected nucleophilic chlorination of quinone monoketals mediated
by N,N′-dimethylhydrazine
dihydrochloride . Org. Biomol. Chem. 
2014 , 12 , 2854 –2858 . 10.1039/c4ob00391h .24675905  c Meister A. C. ; Sauter P. F. ; Bräse S. 
A Stereoselective
Approach to Functionalized Cyclohexenones . Eur.
J. Org. Chem. 
2013 , 7110 –7116 . 10.1002/ejoc.201300752 . d Chittimalla S. ; Kuppusamy R. ; Bandi C. 
A Detour Route for
meta Functionalization of Phenols . Synlett 
2014 , 25 , 1991 –1996 . 10.1055/s-0034-1378395 . e Yang W. ; Dong J. ; Wang J. ; Xu X. 
Rh(III)-Catalyzed
Diastereoselective Annulation of Amides with Quinone Monoacetals:
Access to Bridged Nine-Membered Heterocycles via C–H Activation . Org. Lett. 
2017 , 19 , 616 –619 . 10.1021/acs.orglett.6b03777 .28102687 
Reviews see:

a Huang Z.-T. ; Wan M.-X. 
Heterocyclic
Ketene Aminals . Heterocycles 
1994 , 37 , 1233 –1262 . 10.3987/rev-93-sr7 . b Wang K.-M. ; Yan S.-J. ; Lin J. 
Heterocyclic Ketene
Aminals: Scaffolds for Heterocycle Molecular Diversity . Eur. J. Org. Chem. 
2014 , 1129 –1145 . 10.1002/ejoc.201300929 . c Yang L.-F. 
Heterocyclic Ketene Aminals . Synlett 
2014 , 25 , 2964 –2965 . 10.1055/s-0034-1379541 .
a Yu F. ; Yan S. ; Hu L. ; Wang Y. ; Lin J. 
Cascade Reaction of Isatins with
Heterocyclic Ketene Aminals: Synthesis of Imidazopyrroloquinoline
Derivatives . Org. Lett. 
2011 , 13 , 4782 –4785 . 10.1021/ol201783d .21848302  b Zhang Y.-C. ; Liu Z.-C. ; Yang R. ; Zhang J.-H. ; Yan S.-J. ; Lin J. 
Regioselective construction of 1,3-diazaheterocycle fused [1,2-a][1,8]naphthyridine derivatives via cascade reaction of
quinolines with heterocyclic ketene aminals: a joint experimental–computational
approach . Org. Biomol. Chem. 
2013 , 11 , 7276 –7288 . 10.1039/c3ob41200h .24057033 
Yan S. ; Huang C. ; Su C. ; Ni Y. ; Lin J. 
Facile Route
to 1,3-Diazaheterocycle-Fused [1,2b]Isoquinolin-1(2H)-one Derivatives via Substitution-Cyclization Reactions . J. Comb. Chem. 
2010 , 12 , 91 –94 . 10.1021/cc900121c .19911832 
Zhou B. ; Liu Z.-C. ; Qu W.-W. ; Yang R. ; Lin X.-R. ; Yan S.-J. ; Lin J. 
An environmentally
benign, mild,
and catalyst-free reaction of quinones with heterocyclic ketene aminals
in ethanol: site-selective synthesis of rarely fused [1,2-a]indolone derivatives via an unexpected anti-Nenitzescu
strategy . Green Chem. 
2014 , 16 , 4359 –4370 . 10.1039/c4gc00676c .
a Yu F. ; Huang R. ; Ni H. ; Fan J. ; Yan S. ; Lin J. 
Three-component stereoselective synthesis
of spirooxindole derivatives . Green Chem. 
2013 , 15 , 453 –462 . 10.1039/c2gc36552a . b Chen X.-B. ; Liu X.-M. ; Huang R. ; Yan S.-J. ; Lin J. 
Three-Component Synthesis of Indanone-Fused Spirooxindole Derivatives . Eur. J. Org. Chem. 
2013 , 4607 –4613 . 10.1002/ejoc.201300376 .
a Yan S.-J. ; Chen Y.-L. ; Liu L. ; Tang Y.-J. ; Lin J. 
Synthesis of novel tetracyclo-isocoumarins
via AcOH-catalyzed cascade reaction of heterocyclic ketene aminals
with 2,2-dihydroxy-2H-indene-1,3-dione . Tetrahedron Lett. 
2011 , 52 , 465 –467 . 10.1016/j.tetlet.2010.11.100 . b Yu F.-C. ; Chen Z.-Q. ; Hao X.-P. ; Yan S.-J. ; Huang R. ; Lin J. 
Regioselective synthesis of 9,10-dihydro-6H-chromeno[4,3-d]imidazo-[1,2-a]pyridin-6-one derivatives . RSC Adv. 
2014 , 4 , 6110 –6115 . 10.1039/c3ra46428h .
a Li M. ; Zhou Z.-M. ; Wen L.-R. ; Qiu Z.-X. 
Chemistry of Heterocyclic Ketene Aminals: Construction
of Imidazo(pyrido)[1,2-a]pyridines and Imidazo(pyrido)[3,2,1-ij][1,8]naphthyridines
via DABCO-Catalyzed Tandem Annulations . J. Org.
Chem. 
2011 , 76 , 3054 –3063 . 10.1021/jo102167g .21449612  b Li M. ; Shao P. ; Wang S.-W. ; Kong W. ; Wen L.-R. 
Four-Component Cascade Heteroannulation of Heterocyclic
Ketene Aminals: Synthesis of Functionalized Tetrahydroimidazo[1,2-a]pyridine Derivatives . J. Org. Chem. 
2012 , 77 , 8956 –8967 . 10.1021/jo3013836 .22970749  c Ma Y.-L. ; Wang K.-M. ; Lin X.-R. ; Yan S.-J. ; Lin J. 
Three-component cascade reaction synthesis of polycyclic 1,4-dihydropyridine
derivatives in water . Tetrahedron 
2014 , 70 , 6578 –6584 . 10.1016/j.tet.2014.07.017 . d Wang K.-M. ; Ma Y.-L. ; Lin X.-R. ; Yan S.-J. ; Lin J. 
Regioselective synthesis of pyrrolo[1,2-a]imidazoles
and imidazo[1,2-a]-pyridines . RSC Adv. 
2015 , 5 , 36472 –36479 . 10.1039/c5ra04244e .
a Chen X.-B. ; Liu Z.-C. ; Yang L.-F. ; Yan S.-J. ; Lin J. 
A Three-Component Catalyst-Free Approach
to Regioselective Synthesis of Dual Highly Functionalized Fused Pyrrole
Derivatives in Water–Ethanol Media: Thermodynamics versus Kinetics . ACS Sustainable Chem. Eng. 
2014 , 2 , 1155 –1163 . 10.1021/sc500170d . b Chen X.-B. ; Liu Z.-C. ; Lin X.-R. ; Huang R. ; Yan S.-J. ; Lin J. 
Highly Diastereoselective Convergent Synthesis of Polycyclic Pyrroles
with Consecutive Quaternary Stereocenters: Cascade Construction of
Multiple C–C and C–Hetero Bonds . ACS Sustainable Chem. Eng. 
2014 , 2 , 2391 –2398 . 10.1021/sc5004105 .
a Yan S.-J. ; Liu Y.-J. ; Chen Y.-L. ; Liu L. ; Lin J. 
An efficient
one-pot synthesis of heterocycle-fused
1,2,3-triazole derivatives as anti-cancer agents . Bioorg. Med. Chem. Lett. 
2010 , 20 , 5225 –5228 . 10.1016/j.bmcl.2010.06.141 .20655212  b Huang C. ; Yan S.-J. ; Zeng X.-H. ; Dai X.-Y. ; Zhang Y. ; Lin J. 
Biological
evaluation of polyhalo 1,3-diazaheterocycle fused isoquinolin-1(2H)-imine derivatives . Eur. J. Med.
Chem. 
2011 , 46 , 1172 –1180 . 10.1016/j.ejmech.2011.01.036 .21316818 
a Lu S. ; Shao X. ; Li Z. ; Xu Z. ; Zhao S. ; Wu Y. ; Xu X. 
Design, Synthesis,
and Particular Biological Behaviors of Chain-Opening Nitromethylene
Neonicotinoids with Cis Configuration . J. Agric.
Food Chem. 
2012 , 60 , 322 –330 . 10.1021/jf203068a .22122797  b Chen N. ; Meng X. ; Zhu F. ; Cheng J. ; Shao X. ; Li Z. 
Tetrahydroindeno[1′,2′:4,5]pyrrolo[1,2-a]imidazol-5(1H)-ones as Novel Neonicotinoid
Insecticides: Reaction Selectivity and Substituent Effects on the
Activity Level . J. Agric. Food Chem. 
2015 , 63 , 1360 –1369 . 10.1021/jf505281p .25611859  c Bao H. ; Shao X. ; Zhang Y. ; Deng Y. ; Xu X. ; Liu Z. ; Li Z. 
Specific Synergist for Neonicotinoid Insecticides:
IPPA08, a cis-Neonicotinoid Compound with a Unique
Oxabridged Substructure . J. Agric. Food Chem. 
2016 , 64 , 5148 –5155 . 10.1021/acs.jafc.6b01512 .27281691 
Kondo H. ; Taguchi M. ; Inoue Y. ; Sakamoto F. ; Tsukamoto G. 
Synthesis
and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridine carboxylic acids . J. Med. Chem. 
1990 , 33 , 2012 –2015 . 10.1021/jm00169a033 .2163456 
Suryawanshi S. N. ; Pandey S. ; Rashmirathi ; Bhatt B. A. ; Gupta S. 
Chemotherapy
of leishmaniasis
Part VI: Synthesis and bioevaluation of some novel terpenyl S,N- and N,N-acetals . Eur. J. Med. Chem. 
2007 , 42 , 511 –516 . 10.1016/j.ejmech.2006.09.016 .17178176 
Abdelhalim M. M. ; El-Saidi M. M. T. ; Rabie S. T. ; Elmegeed G. A. 
Synthesis
of novel
steroidal heterocyclic derivatives as antibacterial agents . Steroids 
2007 , 72 , 459 –465 . 10.1016/j.steroids.2007.01.003 .17386937 
Mertens H. ; Troschütz R. 
Nitroketenaminale,
5. Mitt.: Synthese von N2-substituierten
2-Amino-3-nitropyridinen als Vorstufen
von Pyrido[2,3-b]pyrazinen (3-Desazapteridinen) . Arch. Pharm. 
1987 , 320 , 1143 –1149 . 10.1002/ardp.198700023 .
a Ma Y.-L. ; Wang K.-M. ; Huang R. ; Lin J. ; Yan S.-J. 
An environmentally benign double Michael addition reaction
of heterocyclic ketene aminals with quinone monoketals for diastereoselective
synthesis of highly functionalized morphan derivatives in water . Green Chem. 
2017 , 19 , 3574 –3584 . 10.1039/c7gc01435j .b Yan S.-J. ; Hu X.-M. ; Lin J. ; Huang R. ; Zi Q.-X.  Morphan derivatives and preparation
method and application . CN107089948A , 2017 .
a Zhang L. ; Dong J. ; Xu X. ; Liu Q. 
Chemistry of Ketene N,S-Acetals:
An Overview . Chem. Rev. 
2016 , 116 , 287 –322 . 10.1021/acs.chemrev.5b00360 .26760899  b Zeng C.-C. ; Liu F.-J. ; Ping D.-W. ; Hu L.-M. ; Cai Y.-L. ; Zhong R.-G. 
One-Pot Electrochemical Synthesis
of Fused Indole Derivatives Containing Active Hydroxyl Groups in Aqueous
Medium . J. Org. Chem. 
2009 , 74 , 6386 –6389 . 10.1021/jo901091s .19575534 
a Pelter A. ; Elgendy S. 
Phenolic oxidation
with (diacetoxyiodo)benzene . Tetrahedron Lett. 
1988 , 29 , 677 –680 . 10.1016/s0040-4039(00)80182-3 . b Mitchell A. S. ; Russell R. A. 
Oxidation with hypervalent iodine
reagents. Part II: Novel cyclohexadienones as precursors for the synthesis
of anthraquinones . Tetrahedron 
1997 , 53 , 4387 –4410 . 10.1016/s0040-4020(97)00110-5 . c Konkol L. C. ; Guo F. ; Sarjeant A. A. ; Thomson R. J. 
Enantioselective
Total Synthesis and Studies into the Configurational Stability of
Bismurrayaquinone A . Angew. Chem., Int. Ed. 
2011 , 50 , 9931 –9934 . 10.1002/anie.201104726 . d Capparelli M. P. ; Swenton J. S. 
A mechanistic study of the thermal
disproportionation reaction of quinone monoketals . J. Org. Chem. 
1987 , 52 , 5360 –5364 . 10.1021/jo00233a010 .
a Trân-Huu-Dâu M.-E. ; Wartchow R. ; Winterfeldt E. ; Wong Y.-S. 
New Cyclohexadienone Derivatives:
Preparation and Chiral Discrimination in High-Pressure Diels–Alder
Cycloadditions . Chem.—Eur. J. 
2001 , 7 , 2349 –2369 . 10.1002/1521-3765(20010601)7:11<2349::aid-chem23490>3.0.co;2-c .11446638  b Ohkata K. ; Tamura Y. ; Shetuni B. B. ; Takagi R. ; Miyanaga W. ; Kojima S. ; Paquette L. A. 
Stereoselectivity
Control by Oxaspiro Rings during Diels–Alder Cycloadditions
to Cross-Conjugated Cyclohexadienones: The SynOxygen Phenomenon . J. Am. Chem. Soc. 
2004 , 126 , 16783 –16792 . 10.1021/ja047027t .15612717  c Yu M. ; Danishefsky S. J. 
A Direct
Route to Fluostatin C by a Fascinating Diels–Alder Reaction . J. Am. Chem. Soc. 
2008 , 130 , 2783 –2785 . 10.1021/ja7113757 .18254631 
a Mertens H. ; Troschütz R. ; Roth H. J. 
Synthese primärer Nitroketenaminale . Arch. Pharm. 
1986 , 319 , 161 –167 . 10.1002/ardp.19863190213 .b Kenda B. ; Quesnel Y. ; Ates A. ; Michel P. ; Turet L. ; Mercier J.  2-oxo-1-pyrrolidine derivatives,
processes for preparing them and their uses . WO 2006128693
A2 , 2006 .

